



Smart Open Services for European Patients

Open eHealth initiative for a European large scale pilot of
patient summary and electronic prescription

D3.2.2 Final definition of functional service requirements- Patient Summary

WORK PACKAGE	WP 3.2
DOCUMENT NAME	Final definition of functional service requirements - Patient Summary
SHORT NAME	D 3.2.2
DOCUMENT VERSION	0.4
DATE	02/06/2010

COVER AND CONTROL PAGE OF DOCUMENT	
Document name:	D3.2.2 Final definition of functional service requirements- Patient Summary
Document Short name:	D 3.2.2
Distribution level	CO
Status	Final
Author(s): Organization:	Clara Vaquerizo ESNA

Dissemination level: PU = Public, PP = Restricted to other programme participants, RE = Restricted to a group specified by the consortium, CO = Confidential, only for members of the consortium.

ABSTRACT
<p>D3.2.2 Final definition of functional service requirements- Patient Summary</p> <p>This document describes the use cases to be found on the epSOS LSP regarding the PS Services, identifying the needed requirements, the dataset of information to be exchanged and possible issues from the users' point of view.</p>

Change History					
Version	Date	Status Changes	From	Details	Review
V0.1	2009-08-28	First draft	ESNA	Based on final version of D3.2.1 with addition of storyboards, the agreed PS dataset and Supervision Services	WP3.2
V0.2	2009-09-30	Second draft	ESNA	To incorporate the changes as a result of the comments made by WP3.2 to version 0.1 and the changes agreed in the Rome meeting on the 17 th of September of 2009	WP3.2
V0.3	2009-10-13	Third draft	ESNA	To incorporate the changes as a result of the comments to version 0.2	WP3.2
V0.4	2009-12-11	Final version	ESNA	It includes the changes after Quality Review	
V0.5	2010-02-23	Inputs from the technical WPs	ESNA	To incorporate the PEB decision (January 14 th Brussels) to leave the requirement “sharing the medication summary as a separate document” for a further step.	WP 3.2
V0.6	2010-05-13	Inputs form semantic WP 3.5	ESNA	Agreements for alignment with WP 3.5, slight changes in the dataset need it. TPM/technical Wpleader: request to add to the document the possibility to share the PS through a PDF format	WP 3.2

TABLE OF CONTENTS

1	FOREWORD	6
2	EXECUTIVE SUMMARY	7
3	INTRODUCTION	11
	3.1 Goal of WP3.2 as stated in Annex I.....	12
4	CONTEXT	13
	4.1 Definition of the Patient Summary.....	13
	4.2 Background and basic concepts around the patient summary	15
	4.2.1 Scope	15
	4.2.2 Out of the scope.....	16
	4.2.3 Principles	19
	4.2.4 Requirements.....	21
	4.2.5 Interdependencies with other Groups.....	22
5	REQUIREMENTS IDENTIFICATION	24
	5.1 Summary actors' description.....	24
	5.2 Agreement on the scope of the use cases	25
	5.3 Description of the Requirements and the Use cases.....	25
	5.3.1 Requirements description	26
	5.3.2 Functional Requirements	26
	5.3.3 Non Functional Requirements.....	26
	5.3.4 Relationship between use cases and requirements	26
6	COMMON STRUCTURE OF PATIENT SUMMARY	26
	6.1 Minimum common structure of Patient Summary (Basic dataset)	26
	6.2 Maximum common structure of Patient Summary (Extended dataset).....	26
7	FUNCTIONAL RELATIONSHIP WITH E-PRESCRIPTION	26
8	ISSUES AND FUNCTIONAL RECOMMENDATIONS	26
	8.1 WP1.2, WP3.3, WP3.9, WP3.10 and PD4	26
	8.1.1 Assistance services	26
	8.2 WP2.1 'Analysis and comparison of legal and Regulatory Issues'	26
	8.3 WP3.5 'Semantic Services'.....	26
	8.4 WP3.9 'Development of proof of concept system for pilot phase' and WP3.10 'Proof of concept testing'	26

9	EXAMPLE OF USE CASES: STORYBOARDS	26
9.1	Classification of mobility.....	26
9.2	Examples of storyboards	26
9.2.1	Incidental (short) stay in a foreign country.....	26
9.2.2	People frequently crossing borders	26
9.2.3	Longer periods of stay in a foreign country.....	26
9.3	Conclusions.....	26
10	TERMINOLOGY.....	26
10.1	Project name.....	26
10.2	Medical terms.	26
10.3	Technical and other Terms	26
11	GLOSSARY	26
12	LIST OF FIGURES.....	26
13	LIST OF TABLES	26
14	Annex A: Analysis beyond the current epSOS LSP scope.....	26
14.1	Approach 'Multiple Patient Summaries'.....	26
14.1.1	Additional Functional Requirements required.....	26
14.1.2	Relationship between use cases and requirements	26
14.1.3	Pros and cons.....	26
14.2	Use case 3: access of the patient to his existing Patient Summaries .	26
14.2.1	Additional Functional Requirements required.....	26
14.2.2	Functional steps of Use Case 3	26
14.2.3	Pros and cons.....	26
15	Annex B: Referring documents	26

1 **1 FOREWORD**

2 epSOS LSP project operates within a complex policy background and focuses on electronic
3 patient record systems, with its initial focus on two cross border services, i.e., Patient
4 Summary and e-Prescribing/e-Dispensing. The aim of the pilot is to demonstrate that it is
5 feasible for any Member State (MS) that already provides these ehealth services to its
6 residents, to create the conditions that will allow to also offer these services to them when
7 they travel abroad to other Member States taking part in the epSOS LSP.

8

9 A relationship of trust between the epSOS LSP MSs must exist as it is established in Annex I.
10 This means that all the countries are integrated on one system of trust, not only functional
11 and technical but also with respect to quality and reliability of the information exchanged
12 between countries. The framework must ensure that Health Care professionals can rely upon
13 the authenticity of the clinical data on which they will base decisions.

14

15 It is important to note that the epSOS LSP services involving Patient Summaries and e-
16 Prescribing/e-dispensing will be offered on a pilot basis and the intention is to gather data
17 and learn from this pilot operation to accelerate deployment of these services. The pilots will
18 test the feasibility and acceptance of the overall functional, technical and legal interoperability
19 of the proposed solutions.

20

21 It is also important to clarify that it is a basic principle of epSOS LSP that the solutions
22 proposed will build interoperability on current national solutions. This means that the
23 exchange of information (Patient Summary) between different epSOS LSP Member States
24 must take into account the existing and under construction solutions and must respect the
25 laws and regulations of these MSs regarding Patient Summary. In the same way, it is not the
26 objective in epSOS LSP to propose new or amendments to existing legislation but rather to
27 create interoperability between existing legal and regulatory frameworks.

28

29

Concepts paper epSOS LSP

30

31 **2 EXECUTIVE SUMMARY**

32 Based on the principles stated in the Foreword, once the common understanding of the
33 Patient Summary service within the epSOS LSP framework has been agreed on and the use
34 cases identified, the goal of this deliverable is to identify the requirements necessary to
35 implement a feasible service adopting the point of view of the Health Care professional and
36 considering the level of maturity of the solutions within the Member States. In consequence,
37 the aim is to focus on strictly necessary requirements in order to achieve a minimum but safe
38 and secure service.

39

40 The discussion and the content regarding this deliverable start from some concepts, ideas
41 and recommendations from WP1.1 'Analysis and Comparison of national plans/solutions'
42 where the solutions of the different countries are analysed, and is based on the outputs of the
43 previous deliverable, D3.2.1 'Draft definition of functional service requirements – Patient
44 Summary', WT5.2.1 'Initial Scope', 'Concepts paper epSOS LSP' and WP2.1 'Analysis and
45 comparison of legal and regulatory issues'. The scope of the document has been defined
46 with the intention of simplifying the services, avoiding already existing complex matters (from
47 the functional and legal perspective) in the different MSs.

48

49 The driving concept followed in WP3.2 has been to keep the medical perspective and clinical
50 purpose while the technical issues are to be managed in other WPs. The methodology
51 carried out in this WP to produce this deliverable has been described in a separated
52 document placed in PP (internal work document,
53 epSOS_WPInitiationDocument_WP3.2_v0.2.doc)

54

55 The primary application of electronic Patient Summary is to provide the Health Care
56 professional with a dataset of essential and understandable health information at the point of
57 care to deliver safe patient care during unscheduled care and planned care with its maximal
58 impact in the unscheduled care. Any access to the Patient Summary information is in the
59 context of a resident of one Member State (country A) visiting another MS (country B) and
60 seeking for Health Care. The PS made available to the Health Care professional of country B
61 should contain updated and reliable information.

62

63

64

65 At European level, it has to be assumed that the patient may have more than one electronic
66 PS, in one or many countries, made available abroad in a structured way compliant with
67 epSOS LSP PS specification. It has been agreed that only one common structured epSOS
68 LSP PS per country visible from outside will be provided. A single (unique) stored European
69 PS is out of the scope of epSOS LSP.

70 It is out of scope of this deliverable to analyze the methodology that each Member State
71 envisions to produce a valid PS. Also medical processes in each Member States are not
72 analysed.

73

74 Cross-border care in epSOS LSP has been conceived around two use cases and foresees
75 both scheduled and unscheduled encounters. Use case 1 refers to an occasional visitor in
76 country B and use case 2 to a regular visitor or long term visitor to country B. In this
77 deliverable both use cases have been analysed together as there are no differences
78 between them in terms of the services and the information requirements by the final user.

79

80 A list of possible cases in which access to the Patient Summary would support better
81 treatment of cross border patients is presented in section 9 (examples of use cases:
82 storyboards).

83

84 The functional requirements identified to fulfil the use cases are related to:

- 85 • assure the security of the service (like for example identification, authentication or patient
86 consent)
- 87 • access the information from/to another country
- 88 • the correct interpretation of the information
- 89 • meet the information needs of the physician
- 90 • the minimum information needed to fulfil all steps of the PS service.

91

92 In addition to the functional requirements, non functional requirements have been identified
93 as they are needed to fulfil the functional ones and are directly related to the HCP experience
94 and to the security of the process from the functional point of view.

95

96 This is the list of the identified requirements:

97

Functional Requirements

FR01	HCP Identification and authentication
FR02	Trust between countries
FR03	Patient identification
FR04	Patient consent to access data
FR05	Structured Information

FR06	Equivalent Information
FR07	Information Understandable
FR19	Patient summary of country A available
FR20	Information Traceability

Non Functional Requirements

NFR01	Service availability
NFR02	Communications
NFR03	Response time
NFR04	Confidentiality
NFR05	Access control
NFR06	Audit Trail
NFR07	Integrity
NFR08	Non repudiation
NFR09	Trust between countries
NFR10	Guaranteed delivery
NFR12	Supervision services

98

99 It is important to note that description of Use Cases and Functional Requirements have been
100 done with the approach: 'Only the PS of country A (which is the MS of affiliation) will be
101 shown to HCP of country B'. This decision was agreed within the WP in order to reduce
102 complexity and facilitate the viability of the pilots in the epSOS LSP scenario. Nevertheless,
103 the approach 'Multiple PSs' (meaning this that the Health Care professional gets access to
104 the list of existing PSs for that patient and selects and asks for any of them) is presented in
105 Annex A of this deliverable for information purposes in preparation of a possible future
106 epSOS LSP scope extension.

107

108 It is also an objective of this WP to agree on the Patient Summary dataset to be exchanged
109 (epSOS LSP PS) not only on the minimum data set but also in the maximum dataset. It has
110 been agreed that the Patient Summary dataset has to be defined from the medical
111 standpoint. This common and agreed structure of the fields in the PS (epSOS LSP PS) will
112 be represented in each national application as decided by country B. A classification of the
113 different datasets of information identified has been developed based on their degree of
114 relevance in the PS service:

- 115 • 'Minimum dataset' of the PS: is defined as the agreed set of essential health
116 information ('Basic dataset') that is required from the clinical point of view to be sent
117 to deliver safe care to the patient focused in unscheduled care. It may be sent with a
118 value 'null flavor' if the source system of the country does not track that information.
- 119 • 'Mandatory dataset': it is a subgroup of the 'Minimum dataset' and all the fields
120 included in it must have a valid value. If the values are not valid, the PS will be
121 rejected.

- 122 • ‘Maximum dataset’: is an agreed ‘Extended dataset’ or desirable health information
123 from the clinical point of view to be exchanged between the epSOS LSP countries.
124 The fields are not compulsory to be sent.

125

126 The common dataset to be exchanged has been agreed among WP3.2 in a face to face
127 meeting in Paris on July 22nd 2009 and is presented in section 6 (Common structure of
128 Patient Summary).

129

130 During the whole process, a set of issues and recommendations for other WPs have been
131 identified. One of the most important recommendation is addressed to the Semantic WP:
132 coding of the PS information with currently available classification systems is strongly
133 suggested to support semantic interoperability services foreseen within the scope of epSOS
134 LSP.

135

136 During the work carried out by WP3.2, it has been also analysed the possible inclusion of a
137 new Use case (Use Case 3): access of the patient to his PSs located in a country different
138 from country A without the intermediation of a HCP. It was agreed that this UC is out of scope
139 of epSOS LSP. This analysis is included in Annex A of this deliverable only for information
140 purposes in preparation of a possible future epSOS LSP scope extension.

141

142

143

144 **3 INTRODUCTION**

145 The aim of this document is to identify and describe the service requirements necessary to
146 achieve the general and specific objectives defined in Grant Agreement for Pilot Type A -
147 Annex I in relation with the Patient Summary Services.

148

149 This deliverable is not a self-contained document, which means that it is part of the work of
150 the epSOS Large Scale Pilot (LSP) project and is based on the outputs of Annex I, 'Initial
151 Scope' produced by WP5.2, 'Concepts paper epSOS LSP', WP2.1 'Analysis and comparison
152 of legal and regulatory issues' and final version of D.3.2.1 (Draft definition of functional
153 service requirements-PS) that are used as starting point for the development of the
154 deliverable.

155

156 All the activities carried out within WP3.2 to achieve WP3.2 goals and to produce this
157 deliverable (face to face meetings, specific workshops, conference calls etc), are described
158 in a separated document 'Work methodology' (internal working document, not to be
159 published). The following beneficiaries have contributed to the development and production
160 of this deliverable: ESNA (Spanish Ministry of Health and Social Politics, Spain), LOMBARDY
161 (Regione Lombardia, Italy), ELGA (Task Force ELGA and Austrian Ministry of Health ,
162 Austria), ANDA (Regional Service of Andalucia, Spain), CLM (Regional Health Care Service
163 of Castilla la Mancha, Spain), GIPDMP (Group d'intérêt Public-Dossier Médical personnel,
164 France), INDUSTRY (Industry team), NICTIZ (National IT Institute for Health Care, The
165 Netherlands), NHS (NHS connecting for Health, United Kingdom), ZI (Central Research
166 Institute of Ambulatory Health Care in the Federal Republic of Germany), FHGISST
167 (Fraunhofer Gesellschaft, Germany), MEDCOM (Medcom and Danish National Board of
168 Health, Denmark), IZIP, (IZIP-Internet Access to Patient Electronic Health Record , Czech
169 Republic), SALAR (Swedish Associations of Local Authorities and Regions, Sweden), NHIC
170 (National Health Information Centre, Slovakia),CATA (Fundacio Privada Centre Tic i Salut,
171 Spain), DENA (Federal Ministry of Health, Germany), Gematik (Germany) and FRNA (French
172 Ministry of Health, France).

173

174

175

176 **3.1 Goal of WP3.2 as stated in Annex I**

177 A definition of the functional service requirements for the epSOS LSP System is to be drawn
178 up. The definition is to be based on use cases and to describe system outputs, not
179 processes. Additional requirements and necessary constraints may be incorporated into the
180 specification as appropriate (e.g. data protection requirements). This approach is to be
181 scaled down to PS Services as delimited in the initial scope. Variants/alternatives are
182 documented in Initial Scope of the deliverable, submitted for board decision and the decision
183 implemented in the final version 2 of the deliverable.

184

185 **4 CONTEXT**

186 The proposals in this section have as main antecedents the use cases defined in the Initial
187 Scope, the recommendations made by WP1.1 (D1.1.1), the legal and regulatory
188 requirements and constrains identified in WP2.1 and in the concepts addressed in the
189 epSOS LSP Initial Scope and 'Concepts paper epSOS LSP'.

190 The starting point, as stated in WP1.1, 'Analysis and comparison of national plans/solutions'
191 is that all countries have mayor differences regarding the language, the level of deployment
192 of the Patient Summary services and the eHealth processes, concepts and legislation. The
193 challenge for this WP is to define a common service, as less intrusive as possible, with
194 unified and common understandable concepts and within the current legislations (European
195 and national) in order to provide a safe and added value for the patient if he needs Health
196 Care when travelling abroad.

197

198 **4.1 Definition of the Patient Summary**

199 Patient Summary is understood to be a reduced set of patient's data which would provide a
200 health professional with essential information needed in case of unexpected or unscheduled
201 care (emergency, accident..) and in case of planned care (citizen movement, cross-
202 organisational care path..) being its main purpose the unscheduled care.

203

204 The content of the Patient Summary is defined at a high level as the minimum data set of
205 information needed for Health Care coordination and the continuity of care. As stated in
206 epSOS LSP Initial Scope and to be meaningful, the Patient Summary might contain data
207 such as: (defined in detail in chapter 6):

208 1. Patient's general information (mandatory)

209 2. Medical summary (mandatory)

210 3. Medication summary (mandatory)

211

212 As stated in Initial scope: the Patient Summary does not hold detailed medical history or
213 details of clinical condition or the full set of the prescriptions and medicines dispensed.
214 Detailed and complete data are usually contained in the Electronic Health Record.

215

216 The Patient Summary dataset to be exchanged can be divided as follows, based on their
217 degree of relevance in the PS service:

- 218 o 'Basic dataset': it is defined as a set of essential health information that is
219 required from the clinical point of view to be sent to deliver safe care to the
220 patient (focused in unscheduled care). This is the so called 'Minimum dataset'
221 in the Grant Agreement for Pilot Type A - Annex I. Fields in the Basic dataset
222 must be sent but not necessarily its content. "Null flavor" values are allowed.
223 For example: if the source system of a country does not track the field.
- 224 ▪ 'Mandatory dataset': it is a subgroup of the Basic dataset. However,
225 and this is the difference with the precedent fields, they must have a
226 valid value. If the values are not valid, the PS will be rejected. In
227 section 6.1 it is explained which are the valid values for the fields
228 agreed as mandatory (eg: for 'given name' a valid value must be a
229 valid name).
- 230 o 'Extended': it is defined as the desirable health information from the clinical
231 point of view to be exchanged between the epSOS LSP participants. The
232 fields are not compulsory to be sent (therefore, neither the fields, nor the
233 values are compulsory to be sent). This is the so called 'Maximum dataset' in
234 the Grant Agreement for Pilot Type A - Annex I

235 The fields not belonging to the Minimum or to the Maximum agreed epSOS LSP PS dataset
236 will not be exchanged even if they are available in some countries.

237

238 The Patient Summary dataset to be exchanged (epSOS LSP PS) has been defined from the
239 medical standpoint and has been agreed between epSOS LSP member states not only on
240 the basic dataset but also in the extended dataset (see section 6)¹.

241

242 The Medication Summary, which is part of the PS, is defined as the list of the current
243 medicines, this is, all prescribed medicines whose period of time indicated for the treatment
244 has not yet expired whether it has been dispensed or not. Therefore, it is not necessarily
245 related to the prescription/dispensation process defined in D3.1.2²

¹ Although the clinical point of view was the driving force behind the agreement on the epSOS LSP PS dataset, it is also understood that, in order to make the pilot viable, the basic dataset should be available in all or most of countries that are planning to be a pilot site.

² There was a requirement coming from WP3.1 (Definition of functional service requirements-e-Prescription) regarding the possibility for the pharmacist of consulting the Medication Summary, if in that country is permitted, in order to safely dispense the medicine. This means that the Medication Summary should be accessible independently from the rest of the Patient Summary as the pharmacist is not allowed to access the whole PS in all MSs. However, the feedback from the technical WPs was that it was not possible to implement, within the piloting timeframe, the access to the medication summary as a separate document so at the PEB on Brussels January 14th a decision was taken to leave that requirement for a further step. The 3.1 remaining requirement (mandatory) is the pharmacist's access to CURRENT PRESCRIPTIONS, independently of the data source defined by country A. It was also decided to let the countries that showed interest (Sweden, Denmark, Austria but not from the beginning, and maybe Spain) to share a medication summary within the epSOS project. Those countries committed to give their feed-back to the project.

246 The Patient Summary must be presented in a structured way, this is, in structured modular
247 data groups or sections (sorted under the correct nesting headers) each of them containing
248 related items of information. The main aim of this way of presentation is to facilitate the
249 comprehension of the content of the PS for the HCP and to make it possible for each subset
250 of information to be managed individually when applying semantic services or when applying
251 any kind of translation into the native language of the person requesting the PS consultation.

252

253 The common and agreed structure of the fields in the PS (epSOS LSP PS) will be
254 represented in each national application as decided by country B although, in order to ease
255 the process for the HCP, it is recommended that the information is presented as it is normally
256 done in country B.

257

258 **4.2 Background and basic concepts around the patient summary**

259 In this section a definition of the antecedents and the real scope, specifying what is in and
260 out of WP3.2 within the epSOS LSP Project is stated. A clear differentiation of this deliverable
261 from other deliverables in the project is also specified (e.g. functional requirements are
262 identified, no architectural modelling done; only information necessary for Patient Summary
263 is identified, no data modelling) plus the requirements and assumptions, on which the
264 analysis in this document is based.

265

266 **4.2.1 Scope**

267 The objective of WP3.2 is to define the functional service requirements for the Patient
268 Summary Services as delimited in the Initial Scope. The definition is to be based on the Use
269 Cases described in Initial Scope document and to describe system outputs, not processes.

270

271 Cross-border care in epSOS LSP has been conceived around two use cases and foresees
272 both scheduled and unscheduled encounters. Use case 1 applies when the person is an
273 occasional visitor in country B, for example someone on holiday or attending a business
274 meeting, and use case 2 when the person is a regular visitor to country B, for example
275 migrant workers. These two use cases are analysed in Section 5.2 and 5.3.

276

277

278

279

280

281 The epSOS LSP Initial Scope also makes reference to the following situations: “The situation
282 that needs to be considered is that a conscious or unconscious person visits an HCP and this
283 one wants to make use of the patient summary of the patient which is abroad. This situation
284 can arise in an emergency or be planned”. It is important to notice that the maximum impact
285 of epSOS LSP project will be in the unscheduled scenario.

286

287 Having analysed the use cases defined above, WP3.2 assumed that from the functional point
288 of view the variable “frequency of visit” (occasional and regular) in UC1 and UC2 does not
289 make different use cases in terms of the services and the information requirements by the
290 final user because in both cases the UC starts when the HCP needs access to essential
291 patient information which is in a different country from the country where the patient seeks for
292 care. The Patient Summary dataset to be exchanged is to be applied to all the UCs
293 described in epSOS LSP, this means that the dataset to be exchanged will not be different for
294 each UC defined. For this reason both UCs (UC1 and UC2) will be analysed together in the
295 document as a single use case.

296

297 Following the general approach of Grant Agreement for: Pilot Type A - Annex I, where it is
298 recommended that this project should avoid interfering in the functioning and organization of
299 each country available internally, every MS is responsible for the content of the PS generated
300 in it. This means that it is left to the responsibility of each country when and how the Patient
301 Summary is built as well as other processes bound to the normal development of PS in each
302 country.

303

304 **4.2.2 Out of the scope**

305 This section precisely describes all the issues that are not addressed in this document as
306 they are considered to be beyond the defined scope in the epSOS LSP project.

307 ▪ It is out of scope of epSOS LSP to transfer clinical information from country B
308 (country in which information about a patient is needed in case that the patient needs
309 Health Care) to country A (country where the patient can be unequivocally identified
310 and his data may be accessed) (in ‘Concepts paper epSOS LSP’). Therefore it is out
311 of scope that country B sends a record of the Health Care encounter to country A
312 (epSOS LSP project is about making available to HCP-B the PS of the patient but no
313 other electronic health documents like patient health encounters, electronic health
314 records etc).

- 315
- 316
- 317
- 318
- 319
- 320
- 321
- 322
- 323
- 324
- 325
- 326
- 327
- 328
- 329
- 330
- 331
- 332
- 333
- It is out of scope to provide the HCP with all the health information related to that patient (eg: complete electronic patient record, all health encounters, all laboratory tests, all X-rays exams etc). It is also out of scope in epSOS LSP other potential uses of the PS information (e.g: public health, epidemiology, health management, etc.).
 - It is out of scope to analyse in this deliverable the individual medical processes within each Member State, e.g. the way the HCP perform their work, the way a HCP is identified and authorized etc. Besides, a relationship of trust between the epSOS LSP MSs must exist (e.g. validity of the identity of a professional in other MS) as it is established in Grant Agreement for: Pilot Type A - Annex I. This means that all the countries are integrated on one system of trust (functional and technical) and also with respect to quality and reliability of the information exchanged between countries.
 - It is out of scope to analyze the methodology that each Member State envisions to produce a valid PS and to analyze the consequences of the different methodological approaches (automated extraction of the PS, direct human intervention of a HCP etc) or their possible impact on the reliability of the information.
 - A unique European PS stored is out of the scope (option removed by the Legal team after Legal meeting in Vienna on April 21st 2009).
 - Technical issues are out of scope of WP3.2. They have to be managed in other WP (agreed in WP3.2 Vienna meeting on April 22nd 2009).

334

335

336

337

338

339

340

341

342

343

344

345

346

347 The following tables summarises what is in the scope (Table 1) and out of scope (Table 2) of
 348 WP3.2.

349

IN SCOPE
Service definitions and requirements based on agreed Use Cases
Identification and description of functional requirements including the requirements about the data presentation
Identification and description of additional requirements
Functional definitions and the human understandable description of the data model
Definition of a common structure of PS (minimum and maximum common datasets)
Definition of similarities and differences between PS and eP in the content structure and the requirements
Outline constraints
Outline alternatives (with clarifications and comparison between them)
Recommendations that other WPs must take into account

350

Table 1. Scope of WP3.2

351
352

OUT OF SCOPE
Considering the option 'a unique stored European PS'
Description of the Patient Summary processes in every Member State and the methodologies to produce the PS in each Member State
Description of the legal value of PS in each country
Providing the HCP with all the related health information of the patient
Management of the authentication process of the HCP in his/her system
Description of the individual medical processes within each MS
Management of the identification/authentication/authorisation process of the patient
Architectural and data modelling (will be handled by working group 3.3)
Semantic interoperability (e.g. solve semantic differences such as medication names and clinical terminologies)
Transfer of clinical information from country B to country A
Technical issues related to PS

353
354
355

Table 2. Out of the scope for WP3.2

356 **4.2.3 Principles**

357 The basic principles and framework in the definition of the PS services within the epSOS LSP
358 project are the following:

359

- 360 ▪ The primary purpose of electronic Patient Summary in epSOS LSP is to provide the
361 Health Care Professional (HCP) with a dataset of key health information at the point
362 of care to deliver safe patient care during unscheduled care and planned care having
363 its maximal impact in the unscheduled care. We will not go into what is relevant to
364 each medical specialist (as it could differ depending on the type of physician), but on
365 what is necessary for the unscheduled care. Therefore, the content of the PS is not
366 the entire medical record but the essential patient information to provide the
367 assistance. The electronic patient record, health encounters, discharge letter of a
368 hospital etc they are not, by themselves a PS, because they do not satisfy the criteria
369 of 'essential information' from the clinical point of view inherent to the PS definition. In
370 this sense, the purpose of the PS information is to support the coordination and
371 continuity of Health Care in a pan-European mobility of citizens.

- 372 ▪ Any access to the Patient Summary information is in the context of a resident of one
373 MS visiting another MS (country B) and seeking for Health Care; the HCP-B may
374 need access to the PS that the patient has in country A in order to deliver safe Health
375 Care.
- 376 ▪ The driving concept in the development of this deliverable has been the medical
377 perspective and clinical purpose.
- 378 ▪ Patient can have Patient Summaries in different countries (agreed in WP3.2 Vienna
379 meeting on April 22nd 2009), therefore one citizen could have one PS in each
380 European country. The safekeeping of country X Patient Summary remains to country
381 X. It is also important to state that there is no central European database within
382 epSOS LSP where any patient related data is held.
- 383 ▪ Only one common structured epSOS LSP PS per country visible from outside will be
384 provided. This option was agreed in WP3.2 Vienna meeting on April 22nd 2009 in
385 order to reduce the number of PSs belonging to one single patient as, in some MSs
386 one patient can have more than one PS (eg: one PS per region). This is because it
387 was perceived that it is not possible to define a set of rules to decide the prevalence
388 of the clinical information in the process of its integration: integrating information from
389 many different Summary documents can therefore produce a less useful document
390 with a lot of complementary, redundant or similar information regarding the same
391 issue (eg: allergy to betalactamics, allergy to antibiotics, allergy to penicillin, rash due
392 to penicillin ..etc) .
- 393 ▪ Use cases and functional requirements are described in this deliverable with the
394 approach that the HCP of country B accesses only to the PS of country A. The
395 approach ‘multiple PSs’ (access to the existing PSs in the MSs) is described in Annex
396 A only for information purposes but not included in the technical implementation of the
397 epSOS LSP realm.
- 398 ▪ Independently from the procedure that each country applies to produce a valid PS, it
399 is considered that the information contained in the PS made available to country B is
400 consistent (eg: if the patient is allergic to penicillin, his Medication Summary must not
401 contain Penicillin).
- 402 ▪ Independently from the procedure that each country applies to update the information
403 in their PS, it is considered that the PS made available to country B contains updated
404 and reliable information. In any case, knowledge of the date of last update is critical
405 for the best assessment of the information from the PS query.

- 406 ▪ If the patient has decided to hide any information from his PS in country A, it will not
407 be included in the epSOS LSP PS, therefore such information will not be made
408 available to HCP of country B. Health Care professionals participating in the epSOS
409 LSP pilot should be informed (through the appropriate documents to be addressed by
410 the Legal group) that there can be hidden information about the patient when using
411 the epSOS LSP PS service.
- 412 ▪ Country B will maintain information collected on care episodes for a patient of country
413 A for legal and reimbursement purposes but there is no obligation to maintain health
414 records of any kind beyond any nationally required record keeping for audit purposes.
415 As it was stated before, it is left to country B decision whether to create or not a PS
416 for a patient of country A who seeks for Health Care in country B.
- 417 ▪ Any access from an authorised health professional to the PS will generally take place
418 with a citizen's explicit consent by the means and methodology that the Legal group
419 (WP2.1 'Analysis of legal and regulatory issues') and WP3.6 ('Identity Management')
420 will establish. This issue needs to be analysed by the WP2.1 to address the situations
421 when a patient is unable to give his consent (unconscious, handicapped) and there is
422 a risk for the patient's health.

423

424 **4.2.4 Requirements**

- 425 ▪ A basic requirement to achieve the purpose of PS in epSOS LSP is that the
426 information exchanged must be understandable in both countries involved in the
427 interaction.
- 428 ▪ A basic requirement to achieve the purpose as expressed in the PS in epSOS LSP is
429 to ensure the comprehensibility of the information by the one who receives it. This
430 understandability must be minimally assured by two key elements: concept
431 understanding and text understanding and must take priority over the
432 completeness/exhaustiveness of the provided information. Thus, very special care
433 should be given to the receivers side of the PS, in terms of informing him/her about
434 the meaning of the elements in the patient summary.
- 435 ▪ As from the analysis from D1.1.1, since substantial parts of the content of PSs in the
436 MSs are in free text form, in the local country languages, a solution has to be found to
437 overcome this huge interoperability challenge. The most future-oriented solution could
438 be to find a way of making a patient summary 100% coded, on the epSOS LSP level,
439 enabling translations to and from the local environments.

- 440 ▪ One-to-one and unmistakable identification of the patient must be assured.
- 441 ▪ The protection of personal data, privacy and confidentiality must be assured.

442

443 **4.2.5 Interdependencies with other Groups**

444 These are some of the identified interdependencies between WP3.2 and other WPs within
445 the project:

446

447 Interdependencies between 3.2 and 3.1 ‘Definition of functional service requirements- 448 ePrescription’

449 The structure of the data contained in the Medication Summary (within the PS) is
450 consistent across both WPs, to show coherent information. The definition and content
451 of the medication summary is in the scope of WP3.2.

452

453 Interdependencies between 3.2 and 3.3 ‘System architecture’

454 Data modelling must be done in WP3.3 but the functional definitions and the human
455 understandable description of the data model must be made in WP3.2.

456

457 Interdependencies between 3.2 and 3.5 ‘Semantic Services’

458 In this deliverable, the fields that the PS must contain will be defined. Also the
459 definitions or meanings of these fields but not the possible contents (e.g. the field
460 “active ingredient” will be described in the Medication Summary but the different
461 value sets or library as amoxicillin, acetylcysteine etc will not be identified).

462

463 Interdependencies between 3.2 and 3.6 ‘Identity Management’

464 WP3.6 is in charge to deliver Identification, Authentication and Authorization for
465 patients and HCP/HCPO whereas WP3.2 describes the need for identification which
466 is necessary for UC1&2.

467

468 The following figure depicts the flow of inputs and outputs required from and to other WPs:

Final definition of functional service requirements- Patient Summary




Figure 1. Inputs and outputs required from WP3.2 and to other WPs:

469
 470
 471
 472
 473
 474
 475
 476
 477

478 **5 REQUIREMENTS IDENTIFICATION**

479
480 In this chapter the objective is to describe the agreed Use Cases, to identify the functional
481 requirements and to summarize the responsibilities and actions that are needed per each
482 actor (technical and human) in the epSOS LSP project.

483 **5.1 Summary actors' description**

484 This section deals with the actors involved in the Patient Summary service. Basically, these
485 actors may be categorized as:

486
487 Human actors (individuals):

- 488 ▪ Patient: individual from country A requesting Health Care in country B: This person
489 could need emergency or non emergency care.
- 490 ▪ HCP: It is the health professional who provide the Health Care. The HCP must be
491 registered with at least one HCPO or to a Health Authority belonging to the country
492 that could unequivocal identify him or her. Each country must have a system to check
493 the attributes (right for accessing to the information) of the end user who requests the
494 PS information.

495
496 Institutional actors

- 497 ▪ Health Care Service Providers Organization. They are organizations/Institutions to
498 which the HCP is registered with.. These organizations provide the HCPs a status,
499 identification, an authentication, from which the HCP trust is derived.
- 500 ▪ Health Authorities Institutions: They are generally public institutions which provide the
501 governance of health services within a given territory (province / region / MS level),
502 that assigns and assure the status, the function, and sometime the authentication of
503 HCP. This happens because it has been always assumed the HCPO or the institution
504 has to identify the doctor although some exceptions are possible in some countries,
505 where freedom of medical practice is guaranteed. Even in those cases, a Health
506 Authority Institution should guarantee a proper authentication.

507
508 System actors (information system or provider such as those used to convey information
509 across borders):

- 510 ▪ National Contact Point or NCP: as already set out in the Initial Scope, takes care of
511 external and internal national communication in the epSOS LSP project and the
512 semantic mapping between information on either side. The NCPs will be furthermore
513 responsible towards all MS partners in epSOS LSP for securing that the needed

- 514 processes are properly implemented at their own networks which will be typically
515 points where care is delivered. Regarding the PS services:
- 516 ○ The NCP will deal with the identification of patients and identification and
517 authentication of HCPs.
 - 518 ○ The information is made exchangeable by means of the National Contact
519 Points in the both countries.
 - 520 ○ Country B will handle the PS received from country A.
- 521 ■ The Semantic Services to make understandable the PS originated in country A to an
522 HCP in country B.

523 **5.2 Agreement on the scope of the use cases**

524 After analysing the proposed Use Cases, two main uses cases are identified. The two UCs
525 must be understood as an access to the PS.

526
527 -USE CASE 1: an occasional visitor in country B, for example someone on holiday or
528 attending a business meeting. The distinguishing characteristic is that this type of visit is
529 irregular, infrequent, and may not be repeated. This is a type of incidental encounter where
530 the Health Care professional may have no previous record of the person seeking care.

531

532 -USE CASE 2: the person is a regular visitor to country B, for example someone who lives in
533 one country but works in another country. The distinguishing characteristic is that this type of
534 visit is regular, frequent, and the person seeking care may be accustomed to using services
535 in the country where he or she works as a matter of personal convenience. This is a type of
536 occasional situation where the Health Care professional may have some information
537 available from previous encounters, therefore the patient could have a medical record locally
538 stored in country B, and maybe a PS in country B plus in country A. If this is the case, both
539 PSs should be available for the HCP to be consulted.

540 **5.3 Description of the Requirements and the Use cases**

541 The objective of this section is to describe the set of functional and not functional
542 requirements necessary for the implementation of the use cases. This includes required
543 knowledge (not data) and requirements about how to access and get information.

544

545 Description of Use Cases and Functional Requirements have been done with the approach
546 that HCP of country B accesses only to the PS of country A. This decision was agreed in the
547 face to face meeting in Athens on July 1st 2009 in order to reduce complexity and facilitate
548 the viability of the pilots in the epSOS LSP scenario. Nevertheless, the approach ‘Multiple

549 PSs' (meaning that the Health Care professional gets access to the list of existing PSs for
 550 that patient and selects and asks for any of them) was also analysed by WP3.2 and this
 551 analysis is included in Annex A of this deliverable for information purposes in preparation of a
 552 possible future epSOS LSP scope extension.

553

554 Technical and syntactical interoperability, as well as semantic services will be needed as a
 555 baseline and will be described in other WPs.

556 **5.3.1 Requirements description**

557 The identified requirements are presented in Table 3 . The numbering of the requirements is
 558 not always consecutive in order to have a unique number for the same requirement across
 559 D3.1.2 and D3.2.2 and to avoid duplication of requirement numbering. Those requirements
 560 which are common to D3.1.2 and D3.2.2 may have different actors and different information
 561 to be accessed as in the former document the information to be exchanged is related to the
 562 ePrescription and in the latter to the Patient Summary.

563 The goal of these requirements has been to assure the security of the service, the
 564 accessibility of the information from/to another country, the right interpretation of the
 565 information and the information needed to fulfil the service.

566

Functional Requirements

FR01	HCP Identification and authentication
FR02	Trust between countries
FR03	Patient identification
FR04	Patient consent to access data
FR05	Structured Information
FR06	Equivalent Information
FR07	Information Understandable
FR19	Patient summary of country A available
FR20	Information Traceability

Non Functional Requirements

NFR01	Service availability
NFR02	Communications
NFR03	Response time
NFR04	Confidentiality
NFR05	Access control
NFR06	Audit Trail
NFR07	Integrity
NFR08	Non repudiation
NFR09	Trust between countries
NFR10	Guaranteed delivery
NFR12	Supervision services

567

Table 3. Requirements identification for PS Services

568

569 **5.3.2 Functional Requirements**

570

Functional Requirement 01: HCP Identification & authentication

Requirement FR01	HCP Identification & authentication
Description	The HCP must be unequivocally identified and authenticated in his local system and must be identified according to his/her role/profile.
Associated Goals	<ul style="list-style-type: none"> • To provide security to the process. • To ensure that the HCP is legally allowed to perform the functionalities described in this document. • Prevention of disclosure to unauthorized persons.
Actors	<ul style="list-style-type: none"> • HCP-B • NCP-B

571

572

Functional Requirement 02: Trust between countries

Requirement FR02	Trust between countries
Description	All the countries involved in the project are integrated into one system of trust (functional). It is necessary to have an agreed framework for creating trust, by establishing policies for critical data protection, privacy and confidentiality issues as well as mechanisms for their audit.
Associated Goals	<ul style="list-style-type: none"> • To enable the exchange of information between countries. • To avoid having to identify all professionals and institutions from a foreign country in the country of origin. On the one hand, each HCP will be unequivocally identified and authenticated in his local system and must be identified based on his/her role/profile. On the other hand, Health Care Provider Organisation provides HCP a status, a function, an authentication from which the HCP trust is derived. Furthermore, Health Authorities Institutions assign and assure the status, the role, and sometimes the authentication of HCP.
Actors	<ul style="list-style-type: none"> • HCP-B with rights for accessing PS • NCP-A • NCP-B

573

Functional Requirement 03 - Patient identification

Requirement FR03	Patient identification
Description	<p>The patient needs to be univocally identified in a reliable way (unique and unequivocal ID) to allow the HCP to consult his information³ (after his explicit consent or authorisation). For functional and security purposes in the information usage, the univocally identification of the patient is highly relevant. One-to-one and unmistakable identification of the patient must be assured. Patient authentication will be guaranteed at national level based on the concept of mutual trust.</p> <p>Special attention needs to be paid to people under protection and children as they might not own an identification.</p> <p>The process of identification (positive or negative) must be recorded.</p>
Associated Goals	<ul style="list-style-type: none"> To have certainty of the identity of the patient.
Actors	<ul style="list-style-type: none"> HCP-B with rights for accessing PS NCP-A NCP-B

574

575

576

Functional Requirement 04: Patient consent to access data

Requirement FR04	Patient consent to access data
Description	<p>This requirement is subject to legal aspects defined in WP2.1 'Analysis of legal and regulatory issues' and the different solutions to handle it are described in WP3.6 'Identity Management'.</p> <p>Consent must be given by the patient in country B per request and informed, specific and freely given.</p> <p>It must furthermore enforce the consent by deciding on whether a certain request for data is legitimated by the consent or not (country A can not disclose any information until patient consent has been given in country B).</p> <p>The lifecycle of the consent must be logged in a way that the legitimacy of each request can be reconstructed in retrospect.</p>
Associated Goals	<ul style="list-style-type: none"> Manifesting the legal foundation for a lawful data processing. Granting the patient his specific rights according to data protection regulations. Deciding on whether a certain request for data is legitimated by the consent or not.
Actors	<ul style="list-style-type: none"> HCP-B NCP-A NCP-B

577

578

579

³ The necessary datasets for the HCP in UC1&2 (PS dataset is described in section 6)

Functional Requirement 05- Structured Information

Requirement FR05	Structured Information
Description	<p>The information sent to another country must be structured this is, in structured modular data groups (sorted under the correct nesting headlines) each of them containing related items of information with a unified meaning of fields (e.g. field 'Current Problems/Diagnosis' is properly identified in country A and translated to country B). The information should be presented in his system as decided by country B . However, in order to ease the process for the HCP, it is recommended that the information is presented as it is normally done in country B.</p>
Associated Goals	<ul style="list-style-type: none"> • Safety reason. • HCP understands the meaning of all the fields that are going to be shown to him. • To provide the HCP with the necessary information to deliver safe care to the patient. • To guarantee the safety of the patient through a proper understanding of the received information. • To ensure safety delivery of care to patients thanks to the faithful exchange of meanings between systems and between systems and people. • To reduce time in searching necessary information to provide Health Care to the patient. • To facilitate the later treatment of the information to assure its comprehension through semantic tools, systems of codification or of translation according to how it will be established later in the epSOS LSP project.
Actors	<ul style="list-style-type: none"> • HCP-B • NCP-A • NCP-B

580
581
582

Functional Requirement 06- Equivalent Information

Requirement FR06	Equivalent Information
Description	The information sent to another country must be equivalent in the Meaning, i.e. a unified meaning of the information must be coherent with that system (e.g. the field 'active ingredient' means the same in both countries).
Associated Goals	<ul style="list-style-type: none"> • Safety reasons. • HCP understands the meaning of all the fields that are going to be shown to him. • To provide the HCP with the necessary information to deliver safe care to the patient. • To guarantee the safety of the patient through a proper understanding of the received information. • To ensure safety delivery of care to patients thanks to the faithful exchange of meanings between systems and between systems and people. • To reduce time in searching necessary information to provide Health Care to the patient. • To facilitate the later treatment of the information to assure its comprehension through semantic tools, systems of codification or of translation according to how it will be established later in the epSOS LSP project.
Actors	<ul style="list-style-type: none"> • HCP-B • NCP-A • NCP-B

583

584

Functional Requirement 07: Information Understandable

Requirement FR07	Information understandable
Description	The information sent to another country must be Understandable (language) by the human actors that will make use of it.
Associated Goals	<ul style="list-style-type: none"> • Safety reasons. • HCP understands the meaning of all the fields that are going to be shown to him. • To provide the HCP with the necessary information to deliver safe care to the patient. • To guarantee the safety of the patient through a proper understanding of the received information. • To ensure safety delivery of care to patients thanks to the faithful exchange of meanings between systems and between systems and people.
Actors	<ul style="list-style-type: none"> • HCP-B with rights for accessing PS • NCP-A • NCP-B

585

586

Functional Requirement 19: Patient Summary of country A available

Requirement FR19	Patient summary of country A available
Description	The HCP-B needs to access the Patient Summary of the patient available in country A.
Associated Goals	<ul style="list-style-type: none"> • PS of country A must be available to be requested by HCP of any other country. After the identification of the patient who requests Health Care in country B, HCP-B requests the visualization of the PS the patient has in country A.
Actors	<ul style="list-style-type: none"> • HCP-B with rights for accessing PS • NCP-A • NCP-B

587

588

Functional Requirement 20: Information Traceability

Requirement FR20	Information Traceability
Description	The information describing the process and the data involved in the process must be able to be traced and recovered. This includes all the information that has been considered as basic and extended data in the PS. It also includes such information as the location and the identification of the requester, time of consulting and the rest of the information contained within the PS effectively accessed and transferred to the HCP-B.
Associated Goals	<ul style="list-style-type: none"> • Security reasons. • Legal reasons.
Actors	<ul style="list-style-type: none"> • HCP-B with rights for accessing PS • NCP-A • NCP-B

589

590 **5.3.3 Non Functional Requirements.**

591

Non Functional Requirement 01: Service availability

Requirement NFR01	Service availability
Description	<p>Availability is the property of being accessible and usable upon demand by an authorised entity (ISO 7498-2:1989). There are different causes for technical unavailability (of communications, NCPs, local systems...) of the epSOS LSP service as</p> <ul style="list-style-type: none"> o failure o unplanned stop (bug, random error) o partial planned stop (non optimal running) o planned stop (maintenance, update) <p>Each unpredictable service interruption will be detected as soon as possible. The origin of the failure (HCP system, NCP system, ...) will be explained. It will be notified which systems or types of information cannot be reached at the present time due to circumstances or technical failures. The procedure to follow will be specified in order to come back to a normal mode.</p> <p>Instead of completely unavailability, the service can be degraded. This state needs to be defined and when this happens, the suitable alerts and the procedures to follow will need to be defined.</p>
Associated Goals	<ul style="list-style-type: none"> • The epSOS LSP service will be continuously available.

592

593

Non Functional Requirement 02: Communications

Requirement NFR02	Communications
Description	<p>Information has to travel from one country to another. The epSOS LSP service requires secure communications between different local systems, situated in several countries. The information exchanged between countries must be protected from random errors as well as snooping or hacking attacks. This means:</p> <ul style="list-style-type: none"> • That the parties participating to the communication must be properly identified in both countries • The information exchanged must be protected. • The integrity of all information exchanged during the performance of any of the use cases must be guaranteed. • The session and the information exchanged must be associated with secured data allowing afterward verification.
Associated Goals	<ul style="list-style-type: none"> • To have secure communication means between National Contact Points.

594

595

Non Functional Requirement 03: Response time

Requirement NFR03	Response time
Description	<p>As the information has to travel from one country to another it has to be accessible and available with reasonable response times. Of course, all the countries are integrated on one system of trust. The purpose is to deliver timely requested information to the HCP but always guaranteeing Health Care. An acceptable response time not only applies to the receipt of the information, but also to the identification and authentication of HCP and patient.</p> <p>The system should provide an end to end response time (as experienced by the country B HCP) within a few seconds, possibly no more than 10 seconds⁴.</p>
Associated Goals	<ul style="list-style-type: none"> • Information has to travel from one country to another. The response time could vary depending on the chosen architecture; that is, whether it's centralized or distributed and whether there are several PS or just one per citizen. • The system should provide an acceptable end-to-end response time, not degrading or delaying the already existing services because the patient is waiting while the system accesses and shows the required information. • The access times should be tested continually by the system to give the user some idea of what to expect.

596
597

⁴ The technical groups will have to evaluate the feasibility of this response time. It has to be understood that the 10 seconds limit is not a service level agreement but a proposal of threshold.

598

Non Functional Requirement 04: Confidentiality

Requirement NFR04	Confidentiality
Description	Whenever identifiable medical data is communicated, stored, or processed, the confidentiality of the data must be enforced and safeguarded by the epSOS LSP services (by all actors involved). All communication of identifiable data between the epSOS LSP partners must be performed in a way that prohibits any unwanted disclosure of medical data to any third party. Furthermore, the epSOS LSP services must enforce that any data access is only possible over safeguarded, well-defined interfaces. An unwanted or unlawful disclosure to an unauthorised party must also be prohibited at all times.
Associated Goals	<ul style="list-style-type: none"> • Manifesting the legal foundation for a lawful data processing. • Protecting and safe-guarding the patients medical information. • Ensuring the involved HPC to be fully compliant with their professional code.

599

600

601

Non Functional Requirement 05: Access control

Requirement NFR05	Access Control
Description	Each system must assure that only authorized persons and systems are able to access protected data. As authorisations may involve the existence of a treatment context inside a HCPO, these treatment relationships must be justifiable on demand. The communication partners (origin, destination, and potential facilitators) need to be known to each other with prior positive verification that all involved partners are authentic: security features to be provided by the means of an identity (subjects, actors, objects) and access management.
Associated Goals	<ul style="list-style-type: none"> • For traceability reasons. • For security reasons. • To assure confidentiality. • For confidentiality and integrity of medical data reasons. • To align to the European Data Protection Regulations⁵.

602

603

604

605

606

⁵ From DIRECTIVE 95/46/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 24 October 1995 on the protection of individuals with regard to the processing of personal data and on the free movement of such data.

607

Non Functional Requirement 06: /Audit Trail

Requirement NFR06	/Audit Trail
Description	<p>Any data access or attempt to access medical data through the epSOS LSP services, must be fully transparent and traceable and reproducible e.g. by logging of “who” accessed “which” medical data from “where” at “what” time under “whose” authority. When all audit data is available, a supervision authority must be able to fully recover and reconstruct an access attempt and access path in order to verify its regulatory compliance. The collected data must be available and suitable for scheduled and unscheduled security audits. Extraordinary and/or emergency accesses must be specially marked in order to facilitate the local management of those.</p> <p>All data gathered by the audit services may contain identifiable personal data and must be protected accordingly. Furthermore, since the audit trail may be considered as evidence/proof in potential investigations, all protocols must be fully safeguarded in integrity and confidentiality. Access to the audit trail must be restricted and only be granted to authorised persons with concrete access necessities within epSOS LSP.</p> <p>The audit services of the epSOS LSP services should collect a pre-defined set of operational data in order to provide an adequate quality- and capacity-assessment. These protocols must only be used for continuous service delivery and/or service improvement and must not leave the epSOS LSP context.</p>
Associated Goals	<ul style="list-style-type: none"> • Enabling a transparent and reconstructable system operation. • Documenting compliance and legitimacy of data accesses. • Making the epSOS LSP services auditable.

608

609

Non Functional Requirement 07: Integrity

Requirement NFR07	Integrity
Description	<p>The integrity of the transmitted information must be guaranteed. This requirement guarantees that all transmitted data for a patient arrives at the assessing HCP in country B without any alteration from the NCP in country A. It must be identified that the transmitted data has not been damaged, reduced or altered.</p> <p>Any loss of integrity of the transmitted data must be recognizable by the recipient.</p>
Associated Goals	<ul style="list-style-type: none"> • For safety reasons. • To transmit the patient summary unaltered (integer). • To enable detection of any damage, reduction or alteration of the patient summary.

610

611

612

Non Functional Requirement 08: Non repudiation

Requirement NFR08	Non-repudiation
Description	The issuer of the transmitted information must be held accountable for this. This requirement guarantees that medical data from a patient at the assessing HCP in country B is supported by the necessary assurance about the issuer of the information. It must remove the possibility that the issuer of information denies that the sending has taken place covering also the content.
Associated Goals	<ul style="list-style-type: none"> To guarantee that the issuer of the information agreed in this deliverable to be exchanged, cannot refuse that the issuance has taken place.

613
614

Non Functional Requirement 09: Trust between countries

Requirement NFR09	Trust between countries
Description	<p>All the countries involved in the project are integrated into one system of trust (technical). It is necessary to have an agreed framework for creating trust, by establishing processes and procedures for critical data protection, privacy and confidentiality issues as well as mechanisms for their audit. Such issues include, but are not limited to:</p> <ul style="list-style-type: none"> Identification, authentication and authorisation mechanisms. Security and trust mechanisms. Recording and exchanging patient consent.
Associated Goals	<ul style="list-style-type: none"> To enable the exchange of information between countries. To avoid having to identify all professionals and institutions from a foreign country in the country of origin. On the one hand, each HCP will be unequivocally identified and authenticated in his local system and must be identified based on his/her role/profile. On the other hand, Health Care Provider Organisation provides HCP a status, a function, an authentication from which the HCP trust is derived. Furthermore, Health Authorities Institutions assign and assure the status, the role, and sometimes the authentication of HCP.

615
616

Non functional Requirement 10: Guaranteed delivery

Requirement NFR10	Guaranteed delivery
Description	When information is sent from one country to another, it must be assured that the information has been properly received by the end user (HCP of country B).
Associated goals	<ul style="list-style-type: none"> For security reasons. To check that the Patient Summary service has been properly completed.

617
618

Non functional Requirement 12: Supervision services

Requirement NFR12	Supervision services
Description	A service must be put in place to detect all the technical exceptions and to check and monitor the performance of the service (time response, communications...) and to alert so that appropriate measures can be performed to solve these exceptions. This requirement will be further described by the technical WPs.
Associated goals	<ul style="list-style-type: none"> • To assure that the system is technically working properly. • To assure the availability and to avoid degradation of the service.

619

620 Further to those requirements the technical work packages leaders plus the TPM (technical
621 project management) agreed in having the possibility of sharing the information through a
622 PDF format on request and in the country A language. That requirement is not mandatory.

623

624 The PDF content should be constraint for what is defined as the dataset of the patient
625 summary in 3.2 in order to be able to maintain a common understanding of what a patient
626 summary is. From a clinical point of view the aim of the group is not to share as much
627 information as possible but to define what a patient summary has to contain and what should
628 be avoided in order to keep its main use: a summary containing all the important information
629 but being easy and quick to be read by a professional [in a short time frame](#).

630

631 However, at first, some countries that use one single document as a source of information
632 are not able to separate the fields to create the PDF with only the information of the dataset
633 defined. Consequently sometimes at this first step of the project the information will be more
634 than the dataset defined because it will have to be what that entire single coded document
635 contains.

636

637 In any case the PDF document will have medical and legal validity and one HCP (in the case
638 of a PS generated and signed by an HCP) or one HCPO (in the case of a PS constructed
639 through different sources of clinical information) will be liable of the data provided.

640

641

642 **5.3.4 Relationship between use cases and requirements**

643 Three major actions are identified for the description of the use cases (UC1&2):

644


UC 1&2 Action list
A: Check Patient ID
B: Verify patient consent
C: Consult Patient Summary of country A

645

646

647 The two UCs are analysed in the following sequence diagram and table description

648



649

650 **Figure 2. Sequence diagram Use Case 1&2: Patient summary occasional and regular**
 651 **visit**

652

653

654

655

656

657

UC 1&2	Patient summary occasional and regular visit	
Goal	The goal of UC 1&2 is to allow the HCP of country B to consult the Patient Summary of country A of the patient seeking for Health Care either in occasional or in regular visit	
Functional Requirements to be fulfilled by country A	FR02: Trust between countries FR03- Patient identification FR04: Patient consent to access data FR05: Structured Information FR06: Equivalent Information FR19: Patient summary of country A available FR20: Information Traceability	
Functional Requirements to be fulfilled by country B	FR01: HCP Identification & authentication FR02: Trust between countries FR03- Patient identification FR04: Patient consent to access data FR05: Structured Information FR06: Equivalent Information FR07: Information Understandable FR20: Information Traceability	
Actors	Human and institutional actors	Technical actors
	<ul style="list-style-type: none"> • Patient • HCP • HCPO 	<ul style="list-style-type: none"> • NCP B • NCP A
Preconditions or requirements	<ol style="list-style-type: none"> 1. Patient request for medical assistance in country B to a HCP 2. PS in country A 3. The HCP is a person legally authorised in country B to provide Health Care and is identified and authenticated in country B⁶ (FR01) 4. A mechanism to validate the identity of the patient and to handle patient consent against country A has to be available at the Point of Care 5. HCP of country B knows the identity of country A 6. The Health Care Professional must be related to at least one HCPO or to a Health Authority. 7. Country B must provide, maintain and support a NCP supporting communication of information with country A and viceversa (FR20) 8. There is a chain of trust between system actors in this process (FR02) 9. The HCP must be able to access the “communication layout” that handles the PS in the European Countries 10. All technical actors involved in the process must be able to retrieve all the information describing the process and the data involved in it (such as the identification of the HCP, the identification of the patient, the information contained in the PS...), all this information must be able to be traced and recovered (FR20) 	
Post conditions	<p>The HCP-B gets access to the PS (of country A) of the patient at the point of care</p> <p>The information exchanged must be understandable in both countries involved resolving semantic differences such as medication names and clinical terminologies. Syntactical interoperability and record of the access must be done.</p>	

⁶ It is important to emphasize that there might be different definitions of roles/attributes of the end user in each Country (e.g.: patient, physician, pharmacist) which is based on national law. This means that the rights for accessing the information based on the profile of the HCP could be different in each Country

Normal sequence	
Step	Actions (or description)
	A: Check Patient ID FRs fulfilled: FR 03
1.	A patient from country A visits a HCP in country B seeking for Health Care assistance
2.	Patient is identified
3.	The HCP requests the validation of the identity of the patient through the HCP interface
4.	The HCP interface conveys this request to the NCP of country B
5.	The NCP of country B conveys this request to the NCP of country A
6.	The NCP of country A checks ID and provides to the NCP of country B the (positive or negative) patient's identification confirmation.
7.	The NCP of country B provides the patient's identity confirmation to the HCP interface
	B: Patient consent (per request) FRs fulfilled: FR 04
8.	Once the identity of the patient is validated, the patient consent is verified ⁷
	C: Consult PS of country A FRs fulfilled: FR 05, 06, 07, 19,
9.	Once the identity of the patient is validated, the HCP of country B requests, with the consent of the patient (FR04), the PS of country A that can be visualized by HCP interface
10.	The HCP interface requests the PS of country A to the NCP of country B
11.	The NCP of country B requests PS of country A to the NCP of country A
12.	The NCP of country A, after checking if patient consent has been provided, gets and provides to the NCP of country B the PS of country A on the epSOS LSP format.
13.	The NCP of country B conveys the PS of country A to HCP interface
14.	The HCP-B accesses to the Patient Summary of country A
15.	The use case is terminated
Exceptions⁸	
The identity of the patient cannot be properly validated in country A	
6	The NCP of country A informs the NCP of country B of the identification failure
7	The NCP of country B informs the HCP interface of the identification failure
8	The HCP informs of this failure to the patient. The validation of the identification might be requested again many times ⁹ and if not possible the use case is terminated. Should the validation be successful, the use case is resumed at step 6
Denial of Patient Consent	
8	If patient consent is not given by the patient or it can not be recorded in country B, the use case is terminated.
Patient consent can not be checked	
12	If country A can not check that patient consent has been given, a notification is sent to country B and the PS of country A is not provided. The use case is terminated

⁷ This point is subject to Legal aspects defined in WP2.1 and the different solutions to handle it are described in WP3.6. The Legal group will have to address the situations when the patient is a child, a person under guardianship or is unable to give his consent (eg: unconscious) and there is a risk for the patient's health.

⁸ The numbers under "Exceptions" refer to the 'steps' numbers in the 'Normal sequence' section of this table.

⁹ This issue is to be addressed by the technical groups (eg: WP3.7 'Security Services')

Patient Summary does not exist in country A	
11	The HCP informs of this situation to the patient.. The use case is terminated.
Patient Summary can't be retrieved from NCP A	
11	The HCP informs of this failure to the patient. The solicitation to the PS might be requested again many times ⁹ and if not possible the use case is terminated. Should the validation be successful, the use case is resumed at step 12
The communication is broken somewhere during the process (steps A,B,C)	
	The HCP needs to be informed of the issue and the probable cause.
	The HCP informs of this issue to the patient. The process can be repeated again many times ⁹ and if not possible the use case is terminated. This issue has to be logged and reported

658 **Table 4. Use case 1&2 description: Patient summary occasional and regular visit**

659

660

661

662 **6 COMMON STRUCTURE OF PATIENT SUMMARY**

663 This section contains the proposal agreed by WP3.2 on the epSOS LSP Patient
664 Summary dataset. It has been defined according to the clinical point of view keeping in
665 mind the medical perspective of the final user (expectations of the HCP) and the
666 framework described in section 4 ('Context') of this deliverable.

667

668 Based on their degree of relevance in the PS service, the different dataset of information
669 identified have been classified into two categories: 'Basic dataset' and 'Extended dataset'
670 The agreed definition of the Basic dataset (or the 'Minimum dataset') and the 'Extended
671 dataset' (or the Maximum dataset') has been described in section 4.1 of this document.

672

673 The data items should enable an unambiguous interpretation of their contents. All these
674 fields are required to be filled using standards as much as possible. It has to be clearly
675 stated that full codification structure of the PS must be accepted as a Project overall goal
676 to be mandatory reached for a correct full functioning of the whole epSOS LSP system,
677 but that an intermediate phase still relying on some free text will probably be unavoidable.

678

679 During the work carried out within WP3.2. a PS questionnaire was circulated among all
680 countries. The objective was to find out the data items used in the different Member
681 States within the PS. It focused on availability of the data item in that Member State and
682 the 'mandatory' attribute of each data item, understanding by mandatory that this data
683 field was needed by law or that was considered as minimum by that Member State. All
684 the responses delivered by the Member States are kept in a separated document
685 (internal working document, WP3_2_Questionnaire_Structure_PS_Results_v0_1.doc).

686

687 **6.1 Minimum common structure of Patient Summary (Basic dataset)**

688 The agreed basic dataset is a very fundamental dataset understood as a set of essential
689 information required by the HCP to provide safe care to a patient in an unscheduled
690 scenario. The agreed fields must be sent even if there is no content available, that is 'null
691 flavor' is allowed (this concept will be explained in detail in WP 3.5).

692

693 The 'mandatory dataset' is a subgroup of the basic dataset which fields must be sent with a
694 valid value, therefore the value must not be left as 'Null'. It is important to notice that for the
695 'mandatory dataset, .a value of 'Not specified' or a value of 'Not known' can be used only if

696 they are recognized as valid values for that field. (e.g: for 'gender' a value of 'Not Specified'
697 may be used as a valid value by some systems, for example in the United Kingdom system).

698 The following, is the agreed mandatory dataset (also depicted in Table 5):

- 699 • Identification: ID univocal. "Not specified" value is not allowed
- 700 • Given Name: "Not specified" value is not allowed
- 701 • Family name/surname: "Not specified" value is not allowed
- 702 • Date of birth: must be expressed as a date or just a year. The date must be a valid
703 date. A code should be found for "not known" date (example: 9/9/9999 or 1/1/1900).
- 704 • Country: "Not specified" value is not allowed
- 705 • Date of Last Update of PS: It refers to the last version of the PS. It should be a valid
706 date. "Not specified" value is not allowed. It was agreed that it will not be accepted a
707 code for 'not known' date.
- 708 • Other fields will be or not included as mandatory pending decision by WP3.6 (Identity
709 management) because in some countries these fields are needed for identification
710 issues

711 **6.2 Maximum common structure of Patient Summary (Extended dataset)**

712 It is also an objective of WP3.2 to identify and agree on the maximum epSOS LSP PS
713 dataset although, the exchange of this sets of information has a lower priority for the pilot
714 that will be developed in epSOS LSP. Therefore, neither the fields, nor the values are
715 compulsory to be sent.

716

717 In the following table, the structure of epSOS LSP PS is presented (Table 5) with the items
718 that has been agreed by WP3.2 to be included in the Basic, the Mandatory and the
719 Extended dataset according to the definitions provided above. The data elements are
720 presented in structured data groups, each of them containing related items of information.
721 They are shown taking into account that they are a defined set of key data without any
722 architectural or data modelling consideration which is out of the scope of this document and
723 will be handled by WP3.3. To understand the defined dataset, a column named 'comments'
724 with the functional definition and examples of the items to be shared, has been included (to
725 provide a human understandable description of the data model).

726

727

Final definition of functional service requirements- Patient Summary

PATIENT DATA					
VARIABLE (nesting level 1)	VARIABLES (nesting level 2)	VARIABLES (nesting level 3)	DEFINITION AND COMMENTS	BASIC (Basic)/EXTENDED (Ext) DATASET	MANDATORY Yes/No
Identification ¹⁰	National Health Care patient ID	National Health Care patient ID	Country ID, unique for the patient in that country. Example: ID for United Kingdom patient	Basic	Yes
Personal information	Full Name	Given name	The Name of the patient (Example: John). This field can contain more than one element	Basic	Yes
		Family name/Surname	This field can contain more than one element. Example: Español Smith	Basic	Yes
	Date of Birth	Date of Birth	This field may contain only the year ¹¹ if day and month are not available. Eg: 01/01/2009	Basic	Yes
	Gender	Gender Code	It must contained a recognized valid value for this field	Basic	Pending decision by WP3.6 (in some countries 'gender' is needed for univocal identification of the patient)
Contact information	Address ¹²	Street	Example: Oxford	Ext	No
		Number of Street	Example: 221	Ext	No
		City	Example: London	Ext	No
		Post Code	Example: W1W 8LG	Ext	No
		State or Province	Example: London	Ext	No
		Country	Example: UK	Ext	No
	Telephone No	Telephone No	Example: +45 20 7025 6161	Ext	No
	E-mail	E-mail	Example: jens@hotmail.com	Ext	No
	Preferred HCP/Legal organization to contact ¹³	Name of the HCP/Legal organization	Name of the HCP/name of the legal organization. If it is a HCP, the structure of the name will be the same as described in 'Full name' (Given name, family name/surname)	Basic	No
Telephone No		Example: +45 20 7025 6161	Basic	No	
E-mail		E mail of the HCP/legal organization	Basic	No	

¹⁰ Data set that enable the univocal identification of the patient. It will be defined in WP3.6 'Identity Management'. The variable 'Birth place' (Country of birth and place of birth) needs to be evaluated by WP3.6 as in some countries it is needed for univocal identification of the patient.

¹¹ To be aligned with prescription minimum dataset (in D3.1.2 'Final definition of functional service requirements-ePrescription')

¹² Will be adapted due to the variability of the countries.

¹³ A foreign HCP may need a contact (HCP/legal organization) who knows the patient

Final definition of functional service requirements- Patient Summary

	Contact Person/ legal guardian (if available)	Role of that person	Legal guardian or Contact person	Ext	NO
		Given name	The Name of the Contact Person/guardian (example: Peter. This field can contain more than one element)	Ext	No
		Family name/Surname	This field can contain more than one element. Example: Español Smith	Ext	No
		Telephone No	Example: +45 20 7025 6161	Ext	No
		E-mail		Ext	No
Insurance information	Insurance Number	Insurance Number	Example: QQ 12 34 56 A	Pending decision by WP3.6 of including it in Basic (in some countries 'Insurance Number' is needed for univocal identification of the patient).	Pending decision by WP3.6 of including it in Basic (in some countries 'Insurance Number' is needed for univocal identification of the patient).

728

Final definition of functional service requirements- Patient Summary

729

PATIENT CLINICAL DATA					
VARIABLE (nesting level 1)	VARIABLES (nesting level 2)	VARIABLES (nesting level 3)	COMMENTS	BASIC (Basic)/EXTENDED (Ext) DATASET	MANDATORY Yes/No
Alerts	Allergies and intolerances	Allergy description	Description of the clinical manifestation of the allergy reaction. Example: Anaphylactic shock, angioedema (the clinical manifestation also gives information about the severity of the observed reaction)	Basic	No
		Allergy description id code	Normalized identifier	Basic	No
		Onset Date	Date of the observation of the reaction	Ext	No
		Agent	Describes the agent (drug, food, chemical agent, etc) that is responsible for the adverse reaction	Basic	No
		Agent id code	Normalized identifier	Basic	No
History of past illness	Vaccinations	Vaccinations	Contains each disease against which immunization was given	Ext	No
		Brand name		Ext	No
		Vaccinations id code	Normalized identifier	Ext	No
		Vaccination Date	The date the immunization was received	Ext	No
	List of Resolved, Closed or Inactive problems	Problem Description	Problems or diagnosis not included under the definition of 'Current problems or diagnosis'. Example: hepatic cyst (the patient has been treated with an hepatic cystectomy that solved the problem and therefore it's a closed problem)	Ext	No
		Problem Id (code)	Normalized identifier	Ext	No
		On set time	Date of problem onset	Ext	No
		End date	Problem resolution date	Ext	No
		Resolution Circumstances	Describes the reason by which the problem changed the status from current to inactive (e.g. surgical procedure, medical treatment, etc). This field includes 'free text' if the resolution circumstances are not already included in other fields. Example: It can happen that this field is already included in other like Surgical Procedure, medical device etc, eg:	Ext	No

Final definition of functional service requirements- Patient Summary

PATIENT CLINICAL DATA					
VARIABLE (nesting level 1)	VARIABLES (nesting level 2)	VARIABLES (nesting level 3)	COMMENTS	BASIC (Basic)/EXTENDED (Ext) DATASET	MANDATORY Yes/No
			hepatic cystectomy (this will be the 'Resolution Circumstances' for the problem 'hepatic cyst' and will be included in surgical procedures)		
	Surgical Procedures prior to the past six months	Procedure description	Describes the type of procedure	Ext	No
		Procedure Id (code)	Normalized identifier	Ext	No
		Procedure date	Date when procedure was performed	Ext	No
Medical problems	List of Current Problems/Diagnosis.	Problem/diagnosis description	Problems/diagnosis that fit under these conditions: conditions that may have a chronic or relapsing course (eg: exacerbations of asthma, irritable bowel syndrome), conditions for which the patient receives repeat medications (eg: diabetes mellitus, hypertension) and conditions that are persistent and serious contraindications for classes of medication (eg: dyspepsia, migraine and asthma)	Basic	No
		Problem Id (code)	Normalized identifier	Basic	No
		Onset time	Date of problem onset	Basic	No
	Medical Devices and implants	Device and implant Description	Describes the patient's implanted and external medical devices and equipment that their health status depends on. Includes devices as cardiac pacemakers, implantable defibrillator, prosthesis, ferromagnetic bone implants etc that are important to know by the HCP	Basic	No
		Device Id code	Normalized identifier	Basic	No
		Implant date		Basic	No
	Major Surgical Procedures in the past 6 months ¹⁴	Procedure description	Describes the type of procedure	Basic	No
		Procedure Id (code)	Normalized identifier	Basic	No
		Procedure date	Date when procedure was performed	Basic	No
	Treatment Recommendations	Recommendations Description	Therapeutic recommendations that do not include drugs (diet, physical exercise constraints, etc.)	Ext	No
		Recommendation Id	Normalized identifier	Ext	No

¹⁴ As there is subjectivity in the term 'relevant', the date will be used as the limit to include procedures.
Version 0.4

Final definition of functional service requirements- Patient Summary

PATIENT CLINICAL DATA					
VARIABLE (nesting level 1)	VARIABLES (nesting level 2)	VARIABLES (nesting level 3)	COMMENTS	BASIC (Basic)/EXTENDED (Ext) DATASET	MANDATORY Yes/No
		(code)			
	Autonomy/Invalidity	Description	Need of the patient to be continuously assisted by third parties. Invalidity status may influence decisions about how to administer treatments	Ext	No
		Invalidity Id code	Normalized invalidity ID (if any, otherwise free text)	Ext	No
Medication Summary	List of current medicines. (All prescribed medicine whose period of time indicated for the treatment has not yet expired whether it has been dispensed or not.).	Active ingredient	Substance that alone or in combination with one or more other ingredients produces the intended activity of a medicinal product. Example: Paracetamol	Basic	No
		Active ingredient id code	Code that identifies the Active ingredient	Basic	No
		Strength	The content of the active ingredient expressed quantitatively per dosage unit, per unit of volume or per unit of weight, according to the pharmaceutical dose form. Example: 500 mg per tablet	Basic	No
		Pharmaceutical dose form	It is the form in which a pharmaceutical product is presented in the medicinal product package (e.g. tablets, syrup)	Ext	No
		Number of units per intake ¹⁵	The number of units per intake that the patient is taking. Example: 1 tablet	Basic	No
		Frequency of intakes ¹⁵	Frequency of intakes (per hours/day/month/ week..). Example: each 24 hours	Basic	No
		Duration of treatment ¹⁵	Example: during 14 days	Basic	No
		Date of onset of treatment	Date when patient needs to start taking the medicine prescribed	Basic	No
Social History	Social History Observations	Social History Observations related to: smoke, alcohol and diet.	Example: cigarette smoker, alcohol consumption...	Ext	No
		Reference date range	Example: from 1974 thru 2004	Ext	No
Pregnancy History	Expected date of delivery	Expected date of delivery	Date in which the woman is due to give birth. Year, day and month are required.	Ext	No

¹⁵ Posology has been defined from the functional point of view as containing these three components: number of units per intake, frequency of intakes and duration of treatment:(example: 1 unit/intake every 24 hours for a duration of 14 days

Final definition of functional service requirements- Patient Summary

PATIENT CLINICAL DATA					
VARIABLE (nesting level 1)	VARIABLES (nesting level 2)	VARIABLES (nesting level 3)	COMMENTS	BASIC (Basic)/EXTENDED (Ext) DATASET	MANDATORY Yes/No
			Eg: 01/01/2010		
Physical findings	Vital Signs Observations	Blood pressure	One value of blood pressure which includes: systolic Blood Pressure and Diastolic Blood pressure	Ext	No
		Date when blood pressure was measured	Date when blood pressure was measured	Ext	No
Diagnostic tests	Blood group	Result of blood group	Result from the blood group test made to the patient	Ext	No
		Date	Date in which the blood group test was done. This field may contain only the year if day and month are not available. Eg: 01/01/2009	Ext	No

730
731

PATIENT SUMMARY DATA (Information about the PS itself)					
VARIABLE (nesting level 1)	VARIABLES (nesting level 2)	VARIABLES (nesting level 3)	COMMENTS	BASIC (Basic)/EXTENDED (Ext) DATASET	MANDATORY Yes/No
Country	Country	Country	Name of country A	Basic	Yes
Patient Summary	Date Created	Date Created	Data on which PS was generated	Basic	No
	Date of Last Update	Date of Last Update	Data on which PS was updated (data of last version)	Basic	Yes
Author/Nature of the patient summary	Author of the patient summary	Author oof the patient summary	To highlight if the data is collected manually by an HCP or is collected automatically form different sources (eg: hospital doctor repository, GPs...etc) through predetermine clinical rules.	Basic	No
Legal entity	Responsible of the PS data	Responsible of the PS data	At least an author organization (HCPO) shall be listed. In case there is not HCPO identified at least a HCP shall be listed	Basic	No

Table 5. epSOS LSP Patient Summary data set

732

733

734

735 The field “alerts” was originally defined to include all the important and objective medical information that should be highlighted (such as
736 allergies, thrombosis risk, immune deficit ...etc). When defining the content only allergies and intolerance to drugs appear to be the common
737 understanding and the easiest to be transferred.

738 A lot of surveys are being made in different countries (not only in Europe) to make a more evidence-based definition of what should be inside
739 and what shouldn't in the concept “alerts” so, for at that first step, not enough information could be provided to take a further decision. On the
740 other hand some people proposed that it could be considered more a way to present the information than a different field.

741 The final decision was to keep allergies and intolerance as the content of that field in that first step and to get the subject retaken in epSOS2 for
742 a more complete solution if possible. The feeling was that the concept of alerts is a positive one to be defined in a PS but that no further content
743 could be describe at this moment.

744

745

746 **7 FUNCTIONAL RELATIONSHIP WITH E-PRESCRIPTION**

747

748 During the work carried out in WP3.2 ‘Definition of functional requirements –Patient
 749 Summary’ and WP3.1 ‘Definition of functional requirements –ePrescription’, there has been
 750 a constant process of harmonisation between the ePrescription and the Patient Summary
 751 services to build a coherent and consistent service (the whole service, Patient Summary and
 752 ePrescription). This harmonisation has been performed from different perspectives:

753

- 754 • The requirements identified. Some requirements are common to both services (with the
 755 exception of the actors involved and the exchanged information), for example the security
 756 requirements, and some others are different as the specific objectives of the services are
 757 also different.
- 758 • The information shared and who access to it in the different scenarios.
- 759 • The dependencies between the information exchanged in both services is
 760 analysed in the following table:
 761

762

763

	Medication Summary data	ePrescription data	Dispense medicine data
Fields included			
Active ingredient	Yes	Yes	Yes
Active ingredient id code	Yes	No	No
Posology			
Number of units per intake,	Yes	Yes	No
Frequency of intakes	Yes	Yes	No
Duration of treatment	Yes	Yes	No
Strength	Yes	Yes	Yes
Date of onset of treatment	Yes	Yes (maximum)	No

Date of end of treatment	No	Yes (maximum)	No
Medicinal product package	No	Yes	Yes
Pharmaceutical dose form	No	Yes	Yes
Brand name	No	Yes (maximum)	Yes
Route of administration	No	Yes (maximum)	Yes (maximum)
Number of packages	No	Yes	Yes
Date of issue of the prescription	No	Yes	No
Instructions to patient	No	Yes (maximum)	No
Advise to the dispenser	No	Yes (maximum)	No
Date of the dispense medicine event	No	No	Yes
Substitution	No	No	Yes (maximum)

Table 6. Dependencies between information exchanged

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

It is important to understand that the Medication Summary is not used for dispensing and it does not contain, as defined in chapter 6, the dispensed medicine information. The Medication Summary is not updated with the dispensed medicine information but with the finalisation of the treatment.

Who access to what information depends on the role of the health professional and on the country legislation. In some countries, the prescriber can access to all the fields contained in the Patient Summary. However in this same country, the information that the dispenser is allowed to access could be only the information contained in the Medication Summary. Access to other data in the PS is forbidden to the dispenser.

- 781 • The concepts. A common understanding of the terminology used and of the definition
782 of concepts and the data elements to be exchanged has been achieved to assure the
783 congruence of the whole service.

784

785 Concerning the transfer of information from country B to country A, in the case of a HCP-B
786 consulting the Patient Summary of country A, there is no return of information to country A
787 as it is shown in Figure 2 (sequence diagram use case 1&2). But in the case of the
788 ePrescription services and, in order to guarantee the security of the patient, there is a return
789 of information to country A when dispensing medication in country B (country B must assure
790 that country A has successfully received the information about the medicine(s) dispensed in
791 country B before requesting again the 'available' prescriptions of that patient to country A).
792 When this happens, the Medication Summary is not updated because the dispensed
793 medication is not included in the Medication Summary.

794

795 **8 ISSUES AND FUNCTIONAL RECOMMENDATIONS**

796 As result of work carried out in this WP, a set of recommendations based on the
797 functional requirements specification are delivered to other WP.

798

799 **8.1 WP1.2, WP3.3, WP3.9, WP3.10 and PD4**

800 **Recommendations:**

- 801 • Exceptions to the process, either functional (e.g. the HCP can't retrieve the PS) or
802 technical (e.g. communication problems with retrieving information from a country), have
803 to be measured during the pilot phase and a procedure needs to be put in place in order
804 to evaluate and solve these exceptions.

805 In order to deal with the possible exceptions to the use cases, a structure (human and
806 technical) to control the failures is needed. An information procedure regarding
807 functioning of the service, duties, rights etc, is also needed directed to the potential
808 patients and all the actors involved on the process. WP1.2 'Overall evaluation of the
809 project', WP3.3 'System architecture', WP3.9 'Development of proof of concept system
810 for pilot phase'. WP3.10 'Proof of concept testing' and PD4 'Field testing' should
811 collaborate in this task.

812

813 **8.1.1 Assistance services**

814 The objective of the assistance services is to provide guidelines to epSOS LSP end users
815 (HCPs) in case they need assistance or something goes wrong in the pilot phase during the
816 use of the PS service. Possible errors may be:

- 817 - Wrong identification of a patient
- 818 - Errors in the display of the information

819

820 These assistance services should provide a way to facilitate the use of the services as well
821 as to report possible problems that may appear during their use. In addition, these assistance
822 services should provide recommendations to warn the HCP in case any technical problem
823 appears.

824

825 The following assistance services are recommended:

826 1. Help Desk:

- 827 • Contact Telephone to provide on-line support to HCPs.
- 828 • Email address. An email address within the HCPO should be available to report
829 errors, suggestions and complaints of the HCPs about the epSOS LSP services.

830

831 2. Frequently Asked Questions list (FAQ list):

832 A FAQ list should be easily reachable within the HCPO that is providing the services
833 locally and should include answers to possible misuse, known problems or limitations of
834 the application/services. The following are some examples:

- 835 • What countries can I access to use the epSOS LSP services?
- 836 • Which services and where are available?
- 837 • What is in the scope of the project?
- 838 • What is out of the scope of the project?
- 839 • How do I identify a patient?
- 840 • Why information of a patient is not available? (to have into account possible
841 restrictions because of legal issues or epSOS LSP requirements).

842

843 3. Warnings to the user.

844 Information about possible problems should be provided to the user during the use of the
845 application. These are some of those problems that could be automatically detected:

- 846 • Communication problems
847 A message should appear saying that information cannot be shown due to
848 communication problems and that it should be tried later.
- 849 • Technical problems (e.g. server not working)

850 A message should appear saying that information cannot be shown due to
851 technical problems and that it should be tried later.

852 • Problems in the documents received.

853 There might be problems in the information received because this is incomplete,
854 doesn't fulfil the epSOS LSP requirements, etc (e.g. the information received is
855 incomplete or doesn't fulfil the epSOS LSP requirements)

856 A warning should be displayed saying that the 'information received is not
857 complete'

858

859 **8.2 WP2.1 'Analysis and comparison of legal and Regulatory Issues'**

860 **Issues**

- 861 1. Patient consent: Grant Agreement for Pilot Type A - Annex I establishes
862 unequivocally the need for patient consent as key regulating access by third parties.
863 WP2.1 states that Patient Consent may be requested for access to health data by
864 any trusted entity, anywhere, anytime within the epSOS LSP pilots trusted domains.
865 But if this applies, which guarantees would have country A that the consent has been
866 given by the patient in country B in order to allow access of PS to HCP of country B?
867 The verification of the patient consent has to be defined from WP3.6 together with
868 WP2.1. Another issue to be analysed by the Legal group is to address the situations
869 when the patient is a child, a person under guardianship or is unable to give his
870 consent (unconscious, handicapped) and there is a risk for the patient's health.
- 871 2. The 'Concepts paper epSOS LSP' states that the national regulations in the country
872 of delivery (country B) apply to the episode of care. But, what happens when there is
873 different legislation in the different countries about what information can be seen? If
874 the national regulations in the country of care delivery apply to the episode of care, it
875 can be in conflict with legal rights in some countries where for example a pharmacist
876 can not access the PS of the patient. If this patient is in country B and the pharmacist
877 is allowed to access the PS this will be against the acquired patient legal rights in
878 country A.
- 879 3. The 'Concepts paper epSOS LSP' states that the patient's right to hide information
880 contained in his PS depends on country A legislation. Therefore, if the patient has
881 decided to hide information of his PS in country A, such information will not be made
882 available to HCP of country B. But, can this right be overruled in country B in
883 emergency situations when there is a risk for the patient's life?
- 884 4. It has to be evaluated if it is legally correct that the PS of a patient, generated and
885 kept safe by country A, can be directly imported in the Clinical Record of the ICT

886 system of country B. If the answer is 'yes' it has to be evaluated who holds the data
887 ownership and the responsibility.

888

889 **Recommendations:**

- 890 • WP2.1 will need to make sure that countries are aware of all the possible legal situations
891 identified in this deliverable to be faced during the piloting when signing the Framework
892 Agreement.
- 893 • Establish a European framework to include and solve all these legal issues.
- 894 • When a patient is unable to give his consent (unconscious, handicapped) and there is a
895 risk for the patient's health, patient consent should be overridden. Traceability of accesses
896 has to be assured.
- 897 • Health Care professionals participating in the epSOS LSP pilot should be informed
898 (through the appropriate documents within the Framework agreement) about the PS
899 service to be provided in the cross border scenario during the pilot phase of the project.
900 This will include information such as there can be hidden information about the patient
901 when using the epSOS LSP PS service.
- 902 • We recommend that the ability to hide information should be available to the patient from
903 the point when the information is created and it should be exercised by the patient at any
904 stage.

905

906 **8.3 WP3.5 'Semantic Services'**

907 **Recommendations:**

- 908 • Coding of information with currently available classification systems is strongly suggested
909 to support semantic interoperability foreseen within the scope of epSOS LSP. Also, it is
910 desirable, if the codification system allows it, to have the grading/staging of the diagnosis
911 contained in the the field problems/diagnosis' (current problems and solved problems)
- 912 • The implementation of the whole Patient Summary system will have to address the need
913 to code for each attribute included in the sections of the PS.
- 914 • The fields that are free text should be presented in the original language to avoid possible
915 misunderstanding with automatic translations.

916

917 **8.4 WP3.9 'Development of proof of concept system for pilot phase' and WP3.10**
918 **'Proof of concept testing'**

919 **Recommendations:**

Final definition of functional service requirements- Patient Summary

- 920 • WP3.2 recommends presenting the most important information of the PS preferably in
921 the first screen and an appropriate level of nested screens should allow to easily reach
922 for other less important information. The purpose is to deliver timely and secure Health
923 Care.

924

925 **9 EXAMPLE OF USE CASES: STORYBOARDS**

926 This section illustrates by examples the use of the Patient Summary and how accessing to
927 the Patient Summary would improve the Health Care assistance for cross border patients. It
928 is a rather broad selection of medical topics trying to integrate the general scenarios of
929 unplanned (unpredictable emergency, pre-existing disease, deterioration of known disease)
930 and planned care (including commercial “cosmetic” care). Some of the storyboards include
931 unconscious, uncooperative, minor, disabled, lying and deranged patients.

932

933 **9.1 Classification of mobility**

934 The Storyboards refers to different types of patients around Europe, who can be classified
935 according to the following mobility categories:

936 1. Incidental (short) stay in a foreign country

937 This category includes people who are on the move for a vacation or on business trip
938 (e.g: employees of multinational companies and international organizations such as
939 the EC). The main characteristic of this type is that there is no medical information
940 available in the local Health Care environment of country B..

941

942 2. People frequently crossing borders.

943 The reason for moving could be business (e.g.: migrant workers) or citizen mobility
944 within border regions (e.g. in the Maas-Rhine Euregio between Belgium, the
945 Netherlands and Germany). Contacts with Health Care Systems tend however to be
946 limited to two or three Countries (e.g.: the one of residence and the one where the
947 person works). Previous or historic medical data could be present in country B in this
948 case. The possibility of a structural parallel build up of medical data could exist for this
949 type of mobility.

950

951 3. Longer periods of stay in a foreign country

952 In this category, people move abroad for long periods of time. These are people that
953 migrate for the season, e.g. wintering at the Mediterranean sea. One important
954 characteristic is that these people return to country A, e.g. after 3 months. In this
955 situation previous or historic medical data could also be present in country B. The
956 medical data is built up in a serial way with the medical data build up in country A.

957

958 In all of these identified categories, it could also happen that the patient seeks Health
959 Care in an emergency situation context.

960

961 The scenarios described above can be applied to the use cases defined in epSOS LSP
962 (section 5.2):

963 -Use case 1: when the person is an occasional visitor in country B. For example
964 someone on holiday (category 1) or attending a business meeting (category 1).

965 -Use case 2: when the person is a regular visitor to country B. For example migrant
966 workers (category 2) or migrants for the season (category 3).

967

968 **9.2 Examples of storyboards**

969 In this section a list of storyboards is presented. The design of all cases follow the trail
970 that something relevant can be retrieved from accessing the PS of the patient in country
971 A.

972 The Storyboards are classified in one of the 3 categories stated in the precedent section.

973

974 **9.2.1 Incidental (short) stay in a foreign country**

975 **Storyboard n°1**

976 A 10 year old Italian girl falls of bicycle in Vienna and suffers some minor injury with
977 bruises on both legs. It is in question whether tetanus protection is present. Her tutor is
978 not sure about this.

979 Possible answer from PS: vaccination has been recent, no re-immunisation required.

980

981 **Storyboard n°2**

982 A 19 year old female from Scotland has an epileptic seizure in Barcelona and suffers
983 from an apparent nose fracture. She is disoriented at admission into hospital. Routine
984 exploration before X-ray of the skull reveals an early pregnancy. Being disoriented
985 thereafter she cannot be questioned about this. In her pocket nurses discover a paper
986 prescription for an antiepileptic drug (Valproat). Blood level of the drug is above the
987 recommended therapeutic range. When recovering she reports about a recent change in
988 medication, however cannot recall names and doses. Her pregnancy is a surprise to her,
989 causing massive excitement.

990 Possible answer from PS: patient summary shows current medication, gradual
991 replacement to new drug better suitable for pregnancy is started.

992

993 **Storyboard n°3**

994 A 72 year old male from Prague suffers from a large hemorrhagic stroke during a river
995 Thames city cruise in London. He is accompanied by his wife, who reports about
996 hypertension and heart disease with valve replacement about 5 year ago. Treatment with
997 blood diluting agent (Warfarin) is reported by her, though her husband apparently has
998 omitted recent laboratory controls. Though she is requesting maximum treatment
999 neurosurgeons and anaesthetists are uncertain about a lung infiltration visible on X-ray
1000 and thorax- Computed Tomography. They suspect a lung cancer and are reluctant to
1001 operate.

1002 Possible answer from PS: pulmonary infiltrate has already been reported for several
1003 years leading to assumption of older inactive tuberculosis.

1004

1005 **Storyboard n°4**

1006 A 44 year old Sweden woman develops a urinary tract infection during her holidays in
1007 Greece. Though being uncomplicated she reports about an allergy against an antibiotic
1008 without recalling the name.

1009 Possible answer from PS: a specific antibiotic (Sulphonamide) is not given.

1010

1011 **Storyboard n°5**

1012 G.M is a 18 year old Italian boy. During a vacation in France he suffers from sore throat.
1013 When consulting a local GP he refers about intolerance to “some drugs” but cannot be
1014 more explicit since he left home his own Health Care documentation.

1015 The local GP diagnoses an “acute bacterial tonsillitis”.

1016 Possible answer from PS: consultation of PS shows that G.M. is affected by a “prolonged
1017 QT”, a rare congenital disease which contraindicates a list of drugs with potential
1018 negative effects on cardiac rhythm. Appropriate antibiotic is prescribed.

1019

1020 **Storyboard n°6**

1021 F.L, a 72 year old Spanish man visiting England reports to the London Brompton
1022 Hospital’s emergency room with his wife. He tells a story about repeated fainting
1023 episodes. Unfortunately the couple, which appears to be very worried, shows only limited
1024 knowledge of English language and is able only to tell about cardiac problems with no
1025 further detail.

1026 The emergency room doctors apply therefore to F.L. Patient Summary.

1027 Possible answer from PS: F.L. Patient Summary reports a health history of hypertension
1028 and severe cardiac disrhythmia which required a pacemaker implantation a few months
1029 before. A routine ECG made in the London Brompton Hospital’s emergency room shows

1030 pacemaker malfunction. Happily enough the implanted pacemaker is similar to the ones
1031 used locally. Reprogramming of the pacemaker is subsequently performed. After a short
1032 observation period, the patient is discharged and advised to contact his own treating
1033 cardiologist as soon as back home.

1034

1035 **Storyboard n°7**

1036 HPR, a German 66 year old retiree, is a known Insulin-Dependent Diabetes Mellitus
1037 patient. While on vacation in Italy a pickpocket steals the purse in which HPR carries his
1038 antidiabetic medication.

1039 HPR reports to a nearby hospital to seek for a new insulin prescription.

1040 Possible answer from PS: the emergency room doctor looks in HPR's Patient Summary
1041 to get the appropriate insulin type and dosage and issues a prescription for the
1042 corresponding brand names available on the Italian market.

1043

1044 **Storyboard n°8**

1045 D.R. a 62 year old archaeology academic from Amsterdam is found disoriented and
1046 sweating in his hotel room in Paris where he was scheduled to deliver a lecture.

1047 D.R. is admitted to a nearby hospital's emergency room.

1048 Possible answer from PS: the consultation of DR's Patient Summary excludes previous
1049 major health problems. Blood glucose level is highly abnormal (530 mg/ml). Insulin
1050 treatment is started. After stabilization, D.R. is discharged from hospital and advised to
1051 report to his own GP as soon as back in Amsterdam for appropriate follow up.

1052

1053 **9.2.2 People frequently crossing borders**

1054 **Storyboard n°9**

1055 A 52 year old obese man from Germany suffers from severe immobilizing pain in the hip
1056 after trying to get up from the stairs in front of the Hofburg in Vienna. At hospital X-ray
1057 reveals a hip fracture (caput femoris). The physicians consider this to be an inadequate
1058 trauma, searching for potential reasons such as osteoporosis and bone metastasis.
1059 lumbar X-ray shows sign of osteoporosis and an older vertebral compression fracture.
1060 Exploration reveals nothing but an asthma bronchial controlled by inhalers.

1061 Possible answer from PS: several episodes of prolonged corticoid treatment lead to
1062 diagnosis of corticoid induced osteoporosis.

1063

1064 **Storyboard n°10**

1065 A 49 year old male is picked up by Danish police while walking without orientation on a
1066 rail track in Copenhagen. He is partly disoriented and cannot give conclusive answers
1067 how he got there. He provides working credentials of a company in Denmark and a living
1068 address in Hamburg (Germany). Examination and laboratory results reveal progressed
1069 liver disease and haematological disorder. He reports about a recent hospital treatment in
1070 Germany, but cannot give the name or address of the hospital in Hamburg.

1071 Possible answer from PS: patient is a known alcoholic, receives Thiamine infusion
1072 rapidly.

1073

1074 **9.2.3 Longer periods of stay in a foreign country**

1075 **Storyboard n°11**

1076 A 55 year old chronic dialysis patient from Germany travels to Paris every year for a
1077 trimester. He would require several planned dialysis sessions during the 3 months stay.
1078 The details of the condition have been clarified with the receiving dialysis unit in Paris by
1079 the German physician prior to the travel. Due to an unexpected train strike in France the
1080 journey is however delayed in Lyon. Here his overall condition deteriorates, probably due
1081 to some dehydration and travel stress, and hospital treatment becomes necessary.

1082 Possible answer from PS: yet uninformed physicians in Lyon receive information on
1083 condition and medication.

1084

1085 **9.3 Conclusions**

1086 The precedent section illustrates the use of the Patient Summary as being an important
1087 document to support treatment of previously unknown patients in an unscheduled
1088 scenario. In most of the cases, it would be recommended that the patient would contact
1089 his HCP in country A in order to update its Patient Summary when finishing his stay
1090 abroad. This consideration leaves rooms to seek, in a future extension of present epSOS
1091 LSP Project, for methods to fulfil this task, somehow “closing the information loop” from
1092 country B to country A by IT means.

1093

1094

1095

1096 **10 TERMINOLOGY**

1097 This section summarises the common terminology adopted in the epSOS LSP Project.
 1098 The WP5.2.1 definitions have been used as a starting point. This section also includes
 1099 terminology adopted within the WP3.2 in order to understand the description of the Use
 1100 cases. That last line of each item represents the source from where the definition was
 1101 derived.

1102 **10.1 Project name**

1103 Smart Open Services for European Patients-Open eHealth initiative for a European large
 1104 scale pilot of patient summary and electronic prescription. Project acronym: epSOS LSP

1105 **10.2 Medical terms.**

Active Ingredient	Is defined as a substance that alone or in combination with one or more other ingredients produces the intended activity of a medicinal product. NOTE FOR GUIDANCE ON DATA ELEMENTS AND STANDARDS FOR DRUG DICTIONARIES (EMEA/CHMP/ICH/168535/2005)
Current problems/Diagnosis	Problems/diagnosis that fit under these conditions: conditions that may have a chronic or relapsing course, conditions for which the patient receives repeat medications and conditions that are persistent and serious contraindications for classes of medication epSOS LSP D3.2.2
Adverse Reaction	A response to a medicinal product which is noxious and unintended and which occurs at doses normally used in man for the prophylaxis, diagnosis or therapy of disease or for the restoration, correction or modification of physiological function epSOS LSP D3.2.2
Alerts	Meaning any allergies, adverse reactions and alerts as part of the medical history of a patient epSOS LSP D3.2.2
Allergy agent	Agent (medicinal product, food, chemical agent etc) that is responsible for an adverse reaction epSOS LSP D3.2.2
Brand name	The name, which may be either an invented name not liable to confusion with the common name, or a common or scientific name accompanied by a trade mark or the name of the marketing authorisation holder. DIRECTIVE 2004/27/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human
Closed Problems/diagnosis	Problems or diagnosis not included under the definition of 'Current problems or diagnosis. It's a synonymous of inactive

	problems/resolved problems epSOS LSP D3.2.2
Continuity of care	Component of patient care quality consisting of the degree to which the care needed by a patient is coordinated among practitioners and across organizations and time http://www.astm.org/Standards/E2369.htm
Current prescriptions	Any prescribed medication which period of time indicated for the treatment has not yet expired, whether they have been dispensed or not .This does not mean that is a valid prescription as the time to withdraw the medicine can have expired but the treatment is still on. epSOS LSP D3.1.2 and epSOS LSP D3.2.2
Dose form	Is defined as the physical manifestation [“entity”] that contains the active and/or inactive ingredients that deliver a dose of the medicinal product. The key defining characteristics of the Dose Form can be the state of matter, delivery method, release characteristics, and the administration site or route for which the product is formulated NOTE FOR GUIDANCE ON DATA ELEMENTS AND STANDARDS FOR DRUG DICTIONARIES (EMA/CHMP/ICH/168535/2005)
Episode of care	An interval of care by a HCP for a specific medical problem or condition. It may be continuous or it may consist of a series of intervals marked by one or more brief separations from care, and can also identify the sequence of care (e.g., emergency, inpatient, outpatient), thus serving as one measure of Health Care provided. http://www.mondofacto.com/dictionary/medical.html
ePrescription	Means a prescription for medicines or treatments, provided in electronic format. [Term from D5.2.1, adapted]. epSOS LSP D.2.1.1
General practitioner	A general practitioner (GP) is a physician who provides primary care. A general practitioner treats acute and chronic illnesses and provides preventive care and health education for all ages and both sexes. http://www.medical-solutions.co.za/General_Practitioners.php
Health Care Professional	A doctor of medicine or a nurse responsible for general care or a dental practitioner or a midwife or a pharmacist within the meaning of Directive 2005/36/EC of the European Parliament and of the Council of 7 September 2005 on the recognition of professional qualifications or another professional exercising activities in the Health Care sector which are restricted to a regulated profession as defined in Article 3(1)(a) of Directive 2005/36/EC epSOS LSP D5.2.1
Health Care Service Providers Organization.	An institution, authorized to provide Health Care services, unequivocally identified in the set of the Health Care Institutions epSOS LSP D3.2.2
Mandatory PS dataset	It is a subgroup of the ‘Minimum PS dataset’ in which the fields must have a valid value. If the values are not valid, the PS will be rejected. epSOS LSP D3.2.2
Maximum PS dataset	Desirable health information from the clinical point of view to be exchanged between the epSOS LSP countries. The fields contained within the maximum dataset are not compulsory to be sent. It is also

	called 'Extended dataset' epSOS LSP D3.2.2
Medical device	Any instrument, apparatus, appliance, software, material or other article, whether used alone or in combination, including the software intended by its manufacturer to be used specifically for diagnostic and/or therapeutic purposes and necessary for its proper application, intended by the manufacturer to be used for human beings. Devices are to be used for the purpose of: diagnosis, prevention, monitoring, treatment or alleviation of disease. alleviation of or compensation for an injury or handicap, investigation, replacement or modification of the anatomy or of a physiological process and for control of conception Directive 2007/47/EC
Medical Record:	Is a systematic documentation of a patient's medical history and care. The term 'Medical record' is used both for the physical folder for each individual patient and for the body of information which comprises the total of each patient's health history. Medical records are intensely personal documents and there are many ethical and legal issues surrounding them such as the degree of third-party access and appropriate storage and disposal. Although medical records are traditionally compiled and stored by Health Care providers (HCP) personal health records maintained by individual patients have become more popular in recent years. epSOS LSP D.2.1.1
Medication Summary	All prescribed medicine which period of time indicated for the treatment has not yet expired, whether they have been dispensed or not . It's a synonymous of current medication. It contains the following information of each one: active ingredient, strength, posology (number of units per intake, frequency of intakes (per day/month or week) and duration of treatment) and onset date of treatment. epSOS LSP D3.2.2
Medicinal Product	(a) Any substance or combination of substances presented as having properties for treating or preventing disease in human beings; or (b) Any substance or combination of substances which may be used in or administered to human beings either with a view to restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action, or to making a medical diagnosis.' DIRECTIVE 2004/27/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human
Minimum PS dataset	It is defined as the agreed set of essential health information that is required from the clinical point of view to be sent to deliver safe care to the patient in country B. It may be sent with a value 'null flavor' if the source system of the country does not track that information. It is also called 'Basic PS dataset' epSOS LSP D3.2.2
Patient Summary	Should be understood to be a reduced set of patient's data which would provide a health professional with essential information needed in case of unexpected or unscheduled care (e.g. emergency) and in case of planned care (e.g. citizen movement)

epSOS LSP ANNEXI, D2.1.1 and D5.2.1

Pharmaceutical dose form	A Pharmaceutical Dose Form is the form in which a pharmaceutical product is presented in the medicinal product package as supplied by the marketing authorization holder/manufacturer/distributor (e.g. tablets, syrup) NOTE FOR GUIDANCE ON DATA ELEMENTS AND STANDARDS FOR DRUG DICTIONARIES (EMEA/CHMP/ICH/168535/2005)
Posology	Instruction on number of units per intake, frequency of intakes (per day/month or week) and duration of treatment Real Decreto 1910/84
Surgical procedure	A medical procedure involving an incision with instruments performed to repair damage or a disease in a living body www.wordreference.com/definition
Route of administration	Indicates the part of the body through or into which, or the way in which, the medicinal product is intended to be introduced. In some cases a medicinal product can be intended for more than one route and/or method of administration. NOTE FOR GUIDANCE ON DATA ELEMENTS AND STANDARDS FOR DRUG DICTIONARIES (EMEA/CHMP/ICH/168535/2005)
Strength	The content of the active ingredient expressed quantitatively per dosage unit, per unit of volume or per unit of weight, according to the pharmaceutical dose form. DIRECTIVE 2001/83/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF 6 NOVEMBER 2001 ON THE COMMUNITY CODE RELATING TO MEDICINAL PRODUCTS FOR HUMAN USE
Substance	Any matter irrespective of origin which may be: human, e.g. human blood and human blood products; animal, e.g. micro-organisms, whole animals, parts of organs, animal secretions, toxins, extracts, blood products; vegetable, e.g. micro-organisms, plants, parts of plants, vegetable secretions, extracts; chemical, e.g. elements, naturally occurring chemical materials and chemical products obtained by chemical change or synthesis. DIRECTIVE 2001/83/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF 6 NOVEMBER 2001 ON THE COMMUNITY CODE RELATING TO MEDICINAL PRODUCTS FOR HUMAN USE

1106

1107 **10.3 Technical and other Terms**

Access	The ability to obtain certain services (Health Care, electronic services: patient summary, electronic prescription), as determined by factors such as the availability and affordability of goods and services. epSOS LSP D3.2.2
Attribute based	An attributable role-based access that controls and limits the user access

Final definition of functional service requirements- Patient Summary

access	to the defined services based on his/her role/profile. epSOS LSP D3.2.2
Authentication	Process to verify the claimed identity before authorising a particular action to be performed.
Authorization	Process by which entitlement of a requester, to access or use a given service, is determined. epSOS LSP ANNEXI
Comprehensible	Attribute of a variable that makes it understandable to the user
Country A	Is the Member State of affiliation i.e., the state where the mobile patient is insured. This is the country where the patient can be unequivocally identified and his data may be accessed. To each patient one country is attributed as "country A [Term from D5.2.1, adapted]. epSOS LSP D.2.1.1
Country B	Is the Member State of treatment i.e., where cross-border Health Care is actually provided when the patient is seeking care abroad. This is a country, different from country A, in which information about a patient is needed in case the patient needs Health Care [Term from D5.2.1, adapted]. epSOS LSP D.2.1.1
Cross border service	Services provided in a country different from country A (e.g. Health Care services) epSOS LSP ANNEXI
Demographics	Sufficient data to characterize a person like for example: name, date of birth, gender.. epSOS LSP D3.2.2
Electronic Health Record	A comprehensive, structured set of clinical, demographic, environmental and social data information in electronic form, documenting the Health Care given to a single individual. http://www.astm.org/
European Patients – Smart Open Services	Smart Open Services for European Patients - Open eHealth initiative for a European large scale pilot of patient summary and electronic prescription epSOS LSP D5.2.1
Functional Requirement	Defines a function of a software system or its component. A function is described as a set of inputs, the behavior, and outputs http://en.wikipedia.org/wiki/Functional_requirements
Identification	Assignment of a unique number or string to an entity within a registration procedure which unambiguously identifies the entity. This number or string serves thereafter as an identifier uniquely attached to this entity. i2-Health_D3.1_1.0
National Contact Point (definition needs to be revised in technical WPs)	Single node where a set of functionalities and services is provided at national level for the proper working of the epSOS LSP platform D3.2.1

Final definition of functional service requirements- Patient Summary

Non functional Requirement	Requirement that specify criteria that can be used to judge the operation of a system, rather than specific behaviours. http://en.wikipedia.org/wiki/Non-functional_requirement
Point of Care	is any natural or legal person or any other subject having legal capacity that relies on the usage of personal health related data in order to fulfill tasks or business purposes notwithstanding whether those tasks have been delegated by law or not. epSOS LSP D.2.1.1
Project place	Electronic space for the editorial and management of epSOS LSP project
Reliability	Ability to provide security on the veracity of the information provided. http://thesaurus.reference.com
Use Case	Is a methodology used in systems analysis to identify, organize and describe system requirements involved in Health Care scenarios. Contains all system activities that has significance to the user. www.businessanalysisbooks.com

1108

1109 **11 GLOSSARY**

D1.1.1	Report on Opportunities and constraints of Participating MS architectures
D3.2.1	Draft definition of functional service requirements- Patient Summary
D3.2.2	Final definition of functional service requirements- Patient Summary
D3.1.1	Draft definition of functional service requirements- ePrescription
D3.1.2	Final definition of functional service requirements- ePrescription
EC	European Commission: http://ec.europa.eu/index.htm
her	Electronic Health Record
eP	Electronic Prescription
epSOS LSP	European Patients – Smart Open Services
EU	European Union (Austria, Belgium, Bulgaria, Cyprus, the Czech Republic, Denmark,, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden and United Kingdom)
F.A.Q	Frequently Asked Questions
FR	Functional Requirement
GP	General practitioner
HCP	Health Care Professional
HCPO	Health Care Professional Organization
HCP-A	Health Care Professional of country A
HCP-B	Health Care Professional of country B
ICT	Information and Communication Technologies
ID	Identity
IHE	Integrating the Health Care Enterprise - Europe
IT	Information Technologies
L&R	Legal and regulatory
LSP	Large Scale Pilot
MS	(EU) Member State
NCP	National Contact Point
NCP-A	National Contact Point of country A
NCP-B	National Contact Point of country B
NFR	Non functional requirement
No	Number
PC	Project coordinator
PD3	Project Domain 3
PD4	Project Domain 4
PEB	Project Executive Board

PM	Person month
PoC	Point of Care
PP	Project Place
PS	Patient Summary
PSB	Project Steering Board
TelCon	Conference call
ToC	Table of contents
UC	Use case
WG	Working group
WP	Work package
WPL	Work package leader
WT	Work task
XML	Extended Mark-up Language

1110
1111

1112 **12 LIST OF FIGURES**

1113 Figure 1. Inputs and outputs required from WP3.2 and to other WPs:..... 23
 1114 Figure 2. Sequence diagram Use Case 1&2: Patient summary occasional and regular visit 26
 1115

1116 **13 LIST OF TABLES**

1117 Table 1. Scope of WP3.2 18
 1118 Table 2. Out of the scope for WP3.2 19
 1119 Table 3. Requirements identification for PS Services 26
 1120 Table 4. Use case 1&2 description: Patient summary occasional and regular visit 26
 1121 Table 5. epSOS LSP Patient Summary data set 26
 1122 Table 6. Dependencies between information exchanged 26
 1123 Table 7. Information accessed based on the role of HCP 26
 1124

1125

1126 **14 Annex A: Analysis beyond the current epSOS LSP scope**

1127 In order to prepare effectively for a possible epSOS LSP next phase, this section describes
1128 further functionalities beyond the current spSOS scope that were analysed within WP3.2
1129 with the purpose of a future scalability of the epSOS LSP solution. The aim is to profit from
1130 existing favourable cross border regional environments and present, with information
1131 purposes, possible enhancements to allow beneficiaries to implement additional
1132 functionalities on a voluntary basis and among their MSs in order to learn and prepare
1133 effectively for a possible epSOS LSP future extension.

1134

1135 These are the two additional functionalities described: the approach 'Multiple Patient
1136 Summaries' and a new use case: access of the patient to his Patient Summaries located in
1137 some countries different from country A .

1138 **14.1 Approach 'Multiple Patient Summaries'**

1139 As stated in section 4.2, use cases and functional requirements in this deliverable has
1140 been described considering that the HCP-B accesses only to PS of country A in order to
1141 obtain the needed medical information to deliver safe care to a patient seeking for Health
1142 Care in country B in an unscheduled situation. This means that, if the patient has a PS in
1143 any other country different from country A, the HCP-B will not have access to it, therefore
1144 losing potentially medical information that could be important to know and maybe not
1145 included in the PS of country A (it cannot be assured that PS of country A contains the
1146 most updated information for that patient). Moreover, as it is out of scope of epSOS LSP
1147 to transfer clinical information from country B to country A, the medical information
1148 generated for that patient in any Country different from country A cannot be consulted in
1149 the epSOS LSP scenario.

1150 The approach 'Multiple Patient Summaries' implies that the HCP-B get access to the
1151 existing Patient Summaries for that patient in the different MSs. The HCP-B can then
1152 select and ask for any of them that will be presented to him with the common structure
1153 epSOS LSP PS. With this option of Multiple PSs, the user interfaces have to handle the
1154 possibility of the existence of multiple PS and the presentation of the information about
1155 these PSs. This list should be presented to the HCP-B with the necessary information to
1156 select the required PS (e.g. country of origin of the PS, HCPO, date of the last update).
1157 Nevertheless the existence of a large number of PSs for the same patient should be the
1158 exception.

1159

1160 **14.1.1 Additional Functional Requirements required**

1161 The implementation of the UCs with the approach ‘Multiple Patient Summaries’ requires
 1162 the following additional Functional Requirements (besides the requirements describes in
 1163 section 5.3)

1164

Functional Requirement A01: Patient Summaries available

Requirement FR-A01	Patient Summaries available
Description	The HCP-B needs to access the list of the existing Patient Summaries of the patient.
Associated Goals	<ul style="list-style-type: none"> • PS must be available to be requested by HCP of any other country. After the identification of the patient who request Health Care, in country B, HCP of country B requests through a simple action (just a click) the visualization of the complete list of existing PSs for this patient. • HCP to be able to identify the last updated PS. The HCP must be aware when a new PS about a patient has been generated. • NCP-B asks NCP-A for the list of available PSs, and this list is sent and presented to the requesting HCP including, for each PS, the date of last update.
Actors	<ul style="list-style-type: none"> • HCP-B • NCP-A • NCP- B

1165
1166

Functional Requirement A02: Data presentation

Requirement FR-A02	Data presentation
Description	<p>The HCP should be able to see at a glance the different PSs that patient has and the necessary information to select the required PS. One of the possible ways of presenting the list of the existing PSs is in a table format where each row corresponds to a PS in a country for the identified patient. Therefore, there will be as many rows as existing PSs for that patient.</p> <p>The information that the HCP visualizes and utilizes for selecting the appropriate PS must be: country of origin of the PS, HCPO and date of the last update.</p>
Associated Goals	<ul style="list-style-type: none"> • To provide the HCP/patient with sufficient and key information that enables them to select, among the existing PSs for that patient, the required PS in a simple and comprehensible way and with the minimum actions.
Actors	<ul style="list-style-type: none"> • HCP-B • NCP-A • NCP- B

1167
1168

Functional Requirement A03: Updated Information notification sent to country A

Requirement FR-A03	Updated Information notification sent to country A
Description	Country B will just send to country A a notification that a new generation/update of PS has been done in country B (but will not send medical information). It is left to country A what to do with that information.
Associated Goals	<ul style="list-style-type: none"> To assure that the HCP who did the consultation is aware of all the PSs available and last updates.
Actors	<ul style="list-style-type: none"> NCP-A NCP-B

1169

1170 **14.1.2 Relationship between use cases and requirements**

1171 Four major actions are identified for the description of the use cases:

1172

UC 1&2 Action list
A: Check Patient ID
B: Verify patient consent
C: Consult 'available' Patient Summaries
D: Updated Information notification


1173

1174

The two UCs are analysed with the approach 'Multiple Patient Summaries' in the following sequence diagram and table description.

1175

1176



1177

1178

Figure A1. Sequence diagram Use Case 1&2 with the 'Multiple PSs' approach

1179

1180

UC 1&2	Patient summary occasional and regular visit
Goal	The goal of UC 1&2 is to allow the HCP of country B to consult the Patient Summary/Patient Summaries of country A of the patient seeking for Health Care either in occasional or in regular visit
Functional Requirements to be fulfilled by country A	FR02: Trust between countries FR03: Patient identification FR04: Patient consent to access data FR05: Structured Information FR06: Equivalent information FR19: Patient summary of country A available

	FR20: Information Traceability FRA01: Patient Summaries available FRA02: Data presentation	
Functional Requirements to be fulfilled by country B	FR01: HCP Identification & authentication FR02: Trust between countries FR03- Patient identification FR04: Patient consent to access data FR05: Structured Information FR06: Equivalent information FR07: Information Understandable FR20: Information Traceability FRA03: Updated Information notification sent to country A	
Actors	Human and institutional actors	Technical actors
	<ul style="list-style-type: none"> • Patient • HCP • HCPO 	<ul style="list-style-type: none"> • NCP B • NCP A
Preconditions or requirements	<ol style="list-style-type: none"> 1. Patient request for medical assistance in country B to a HCP 2. PS in a Country different from country B 3. The HCP is a person legally authorised in country B to provide Health Care and is identified and authenticated in country B¹⁶ (FR01) 4. A mechanism to validate the identity of the patient and to handle patient consent against country A has to be available at the Point of Care 5. HCP of country B knows the identity of country A 6. The Health Care Professional must be related to at least one HCPO or to a Health Authority. 7. Country B must provide, maintain and support a NCP supporting communication of information with country A and viceversa (FR20) 8. There is a chain of trust between system actors in this process (FR02) 9. The HCP must be able to access the “communication layout” that handles the PS in the European Countries 10. All technical actors involved in the process must be able to retrieve all the information describing the process and the data involved in it (such as the identification of the HCP, the identification of the patient, the information contained in the PS...), all this information must be able to be traced and recovered (FR20) 	
Post conditions	<p>The HCP-B gets access to the PSs of the patient at the point of care</p> <p>The information exchanged must be understandable in both countries involved resolving semantic differences such as medication names and clinical terminologies. Syntactical interoperability and record of the access must be done.</p>	
Normal sequence		
Step	Actions (or description)	
	A: Check Patient ID	FRs fulfilled: FR 03
1.	A patient from country A visits a HCP in country B seeking for Health Care assistance	
2.	Patient is identified	
3.	The HCP requests the validation of the identity of the patient through the HCP interface	

¹⁶ It is important to emphasize that there might be different definitions of roles/attributes of the end user in each Country (e.g.: patient, physician, pharmacist) which is based on national law. This means that the rights for accessing the information based on the profile of the HCP could be different in each Country

4.	The HCP interface conveys this request to the NCP of country B	
5.	The NCP of country B conveys this request to the NCP of country A	
6.	The NCP of country A checks ID and provides to the NCP of country B the (positive or negative) patient's identification confirmation.	
7.	The NCP of country B provides the patient's identity confirmation to the HCP interface	
	B: Patient consent (per request)	FRs fulfilled: FR 04
8.	Once the identity of the patient is validated, the patient consent is verified ¹⁷	
	C: Consult 'Available' PSs	FRs fulfilled: FR 05, 06, 07, 19, A01, A02
9.	Once the identity of the patient is validated, the HCP of country B requests, with the consent of the patient (FR04), the list of available PSs (for that patient) that can be visualized by HCP interface	
10.	The HCP interface requests the list of available PSs to the NCP of country B	
11.	The NCP of country B requests the list of available PSs to the NCP of country A	
12.	The NCP of country A, after checking if patient consent has been provided, gets and provides to the NCP of country B the list of available PSs on the epSOS LSP format.	
13.	The NCP of country B conveys the the list of available PSs to HCP interface	
14.	The HCP selects a PS from the provided list. The HCP asks to the NCP of country B for the selected PS (a PS either from country A or from a Country different than country A)	
15.	The NCP of country B requests for the selected PS.	
16.	The NCP of country B conveys the selected PS to HCP interface	
17.	The HCP accesses to the Patient Summary he has selected. Afterwards, if he needs to consult any other PS of the available PSs, the process restarts at step 10	
18.	D: Updated Information notification	FRs fulfilled: FR A03
19.	If a PS is created and/or updated in country B (it is left to the country decision to do so), the NCP of country B conveys the notification of this information to the NCP of country A	
20.	The use case is terminated	
Exceptions¹⁸		
The identity of the patient cannot be properly validated in country A		
6	The NCP of country A informs the NCP of country B of the identification failure	
7	The NCP of country B informs the HCP interface of the identification failure	
8	The HCP informs of this failure to the patient. The validation of the identification might be requested again many times ¹⁹ and if not possible, the use case is terminated. Should the validation be successful, the use case is resumed at step 6	
Denial of Patient consent		
8	If patient consent is not given by the patient or it can not be recorded in country B, the use case is terminated	
Patient consent can not be checked		

¹⁷ This point is subject to Legal aspects defined in WP2.1 and the different solutions to handle it are described in WP3.6. The Legal group will have to address the situations when the patient is a child, a person under guardianship or is unable to give his consent (eg: unconscious) and there is a risk for the patient's health.

¹⁸ The numbers under "Exceptions" refer to the 'steps' numbers in the 'Normal sequence' section of this table.

¹⁹ This issue is to be addressed by the technical groups (eg: WP3.7 'Security Services')

	If country A can not check that patient consent has been given, a notification is sent to country B and the list of available PSs is not provided. The use case is terminated
Patient Summaries do not exist	
11	The HCP informs of this situation to the patient. The use case is terminated.
Patient Summaries can not be retrieved from NCP	
11	The HCP informs of this failure to the patient. The solicitation to the PS might be requested again many times ¹⁹ and, if not possible, the use case is terminated. Should the validation be successful, the use case is resumed at step 12
The communication is broken somewhere during the process (steps A,B,C,D)	
	The HCP needs to be informed of the issue and the probable cause.
	The HCP informs of this issue to the patient. The process can be repeated again many times ¹⁹ and if not possible, the use case is terminated. This issue has to be logged and reported

1181 **Table A1. Use case 1&2 description with the 'Multiple PSs' approach**

1182

1183 **14.1.3 Pros and cons**

1184 The pros and cons of the approach 'Multiple Patient Summaries' are analysed in Table
1185 A2 and Table A3.

1186

Pros of 'Multiple PSs' approach
HCP-B get access to consult the information contained in all the existing PSs for that patient
HCP-B get access to the most updated and relevant information as he has access to all the existing PSs for that patient

1187 **Table A2. 'Multiple PSs' approach pros**

1188

1189

Cons of 'Multiple PSs' approach
HCP-B needs more time to access the proper information for each encounter turn into a collection of PS from different countries (list of existing PSs)
Complex legal situations, negotiating the laws of the different countries during the access to the PS.

1190 **Table A3. 'Multiple PSs' approach cons**

1191

1192 **14.2 Use case 3: access of the patient to his existing Patient Summaries**

1193 The Use Case 3 deals with the possibility given to a patient to access to his PS/PSs
1194 generated and kept in other Countries (different from country A) without the presence of a
1195 HCP. This UC must be understood as an access for the patient to visualize his PSs being

1196 out of scope of this UC that the patient records data and any other transaction except the
 1197 record of all the accesses done to his PSs.

1198

1199 The reasons for the inclusion of this UC in a possible future expansion of epSOS LSP are
 1200 based on these antecedents:

- 1201 ▪ This UC was not included in Grant Agreement for Pilot Type A - Annex I but it
 1202 states that the overarching goal of this project is focused in the needs and wishes
 1203 of citizens.
- 1204 ▪ The epSOS LSP Initial Scope document left open the possibility of introducing this
 1205 UC
- 1206 ▪ From the results in D1.1.1 ('Report on Opportunities and constraints of
 1207 Participating MS architectures v1.0.pdf') all Member States but one include this
 1208 service for its citizens within its Countries. The MS not including it does not allow
 1209 by law the patient direct access to his PS information.
- 1210 ▪ The experts WP3.2 meeting held in Prague on February 17th 2009 supported the
 1211 inclusion of this UC in epSOS LSP

1212

1213 **14.2.1 Additional Functional Requirements required**

1214 For the implementation of this UC, an additional Functional Requirements is needed:
 1215 Patient authentication/authorization.

1216

Functional Requirement A04: Patient Authentication/Authorization

Requirement FR-A04	Patient Authentication/Authorization
Description	The patient must be unequivocally authenticated to allow the access to his/her available Patient Summaries in every country
Associated Goals	<ul style="list-style-type: none"> • To provide security to the process • To ensure that the patient is allowed to see in every country the information about his/her Patient Summaries • Prevention of disclosure to unauthorized persons
Actors	<ul style="list-style-type: none"> • Patient • NCP-A • NCP-B

1217

1218

1219 **14.2.2 Functional steps of Use Case 3**

1220 The functional steps of UC3 are depicted in the following figure:

1221




Figure A2. Functional steps of Use Case 3

1222

1223

1224

1225

The steps reported in Figure A2 are as follows:

1226

1227

1228

1229

1230

1231

1232

1233

1234

1235

1236

1237

1238

1239

1. Through a secure web service via NCP of country A, an European citizen (from country A) requests information about his or her PSs in country B
2. The patient asks to be identified and authenticated in country A
3. The patient is identified and authenticated by a national identification service in country A
4. The patient requests the list of his/her available PSs
5. NCP of country A retrieves the existing PSs for the identified patient.
6. The NCP from country A presents to the identified patient the list of his/her PSs.
7. The patient selects the PS to consult through the NCP from country A
8. Translation of the select PS in country A understandable format
9. The NCP A requests the data set of the PS to the NCP of the country that holds the selected PS
10. The patient visualizes through the NCP of country A, the data of the selected PS

1240

14.2.3 Pros and cons

1241 The pros and cons of this UC are analysed in Table A4 and Table A5 The main limitation
 1242 of UC 3 is that it implies difficulties from the technical and from the legal point of view
 1243 (see table A5).

1244

Pros of Use case 3
The main “pro” for this use case is the empowerment of the patient who is in control of access to his medical information.
Although the added value from the Quality of Care point of view is much higher in UC1&2, it is a right of the patient in most of the MSs to direct access to his medical information.
It is considered as a good practice recommended by different organizations
epSOS LSP cross-border Interoperability services are used

1245

Table A4. Use Case 3: pros

1246

Cons of Use case 3
Data protection: how can we determine that the patient is who he says he is (authentication)?
Does patient’s Authentication provides the same level of trust and security of HCP’s Authentication?
How can we ensure the security of the application?
How can we ensure that the patient is able to interpret correctly the information held on their summary?
Country A law authorise a direct access of the patient to his clinical data. According to D1.1.1, only one MS does not allow by law the patient direct access to his PS info
Legal issue: NCP-B should reply to a request coming from a patient. What about if country B does not allow by law patients’ direct access?. The situation could be solved with the Contract.
Legal issue: it might happen that country A does not allow direct access to PS and country A citizen, while in B, requests and gets a country A PS. The situation could be solved with the Contract.
The translation of the PS from another country to the language of the patient has to be managed.

1247

Table A5. Use Case 3: cons

1248

1249 **15 Annex B: Referring documents**

Date	Type	Description	Version	Origin	Document
2008-06-30	Final	This document is a contractual agreement between	June 24 th 2008	EMP/S.O.S. LSP-eHealth team. Grant	Annex I – “Description of Work”

Final definition of functional service requirements- Patient Summary

		the different participants in the project.		Agreement for Pilot Type A - Annex I	
2009-01-28	Final	Document defining the scope of the epSOS LSP at a high level	1.0	epSOS LSP WP5.1	epSOS LSP_ Initial Scope definition
2009-06-01	Final	Report on Opportunities and constraints of Participating MS architectures	1.0	WP1.1: Analysis and comparison of national plans/solutions	D1.1.1 Report on Opportunities and constraints of Participating MS architectures
2009-06-11	Draft	This document is a 'life' document which describes the already approved concepts in epSOS LSP and is to be approved by PEB	0.11	Concepts paper epSOS LSP	The epSOS LSP Trusted Domain(s): CONSOLIDATION OF CONCEPTS
2009-08-20	Final	Final version of D3.2.1 after Quality Review	0.71	epSOS LSP WP3.2	D3.2.1 Draft definition of functional service requirements-PS
2009-02-20	Internal work document	Questionary for the content of the national PS. It collects input from all MSs about availability of the data elements	0.4	epSOS LSP WP3.2	WP3.2_Questionnaire_Structure_PS
2009-02-07	Internal work document	It describes the project plan, methodology, different working groups and tasks description	0.6	epSOS LSP WP3.2	Draft_3.2_project_plan (available in PP)
2009-03-04	Internal work document	It describes the action points, next milestones, meetings and it is constantly updated.	0.3	epSOS LSP WP3.2	ActionPoints_Meetings_WP3.2.xls (available in PP)

1250